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Abstract 
In 2008, 26% of all deaths were cancer-related, making this group of diseases the second leading cause 
of death in the EU countries. Derailment of tyrosine kinase signaling is one important pre-requisite 
towards tumorigenesis. Small molecular inhibitors of receptor tyrosine kinases (RTKs) are a new type 
of targeted therapy and they are increasingly used as a core component of personalized cancer therapy. 
The main aim of this thesis is to investigate the anti-cancer effects of the multi tyrosine kinase inhibitor 
(TKI) sorafenib in hematological and solid tumors. 
In the first study, we found that sorafenib is particularly effective in inducing cell death in a panel of 
human myeloma cell lines. We investigated the mode of cell death induced by sorafenib and found that 
this TKI induces both caspase dependent and caspase independent cell death. Furthermore, sorafenib 
induces autophagy in some human myeloma cell lines, myeloma patient samples and mouse myeloma 
cells and co-treatment of myeloma cells with sorafenib and autophagy inhibitors potentiates the 
cytotoxic efficacy of sorafenib. Importantly, sorafenib induced cell death in freshly isolated CD138+ 
multiple myeloma cells from newly diagnosed patients chemotherapy naïve as well as bortezomib 
resistant patient samples. We investigated the efficacy of sorafenib in the 5T33MM mouse myeloma 
model and found that this TKI lead to significantly increased survival, reduced tumor growth and 
decreased serum M component.  
In the pertaining studies we investigated the efficacy of sorafenib against prostate cancer cell lines. In 
the second study we demonstrated that sorafenib caused a dose-dependent decrease in cell viability in 
two hormone refractory and one hormone responsive prostate cancer cell lines. 
In the third study we further investigated the signaling cascades inhibited by sorafenib leading to cell 
death in prostate cancer cell lines (22Rv1 and PC3). Activation of caspases and downregulation of Mcl-
1 are seen in both cell lines. However we found that distinct upstream signaling cascades are activated 
in these two prostate cancer cell lines which are differentially affected upon treatment with sorafenib.  
In 22Rv1, ERK1/2 is constitutively phosphorylated and active whereas in PC3 cells it is not active. In 
contrast, Src and AKT were constitutively active in PC3 cells but not in 22Rv1 and treatment with 
sorafenib could inhibit these kinases in PC3 cells. In both cell lines, sorafenib induces autophagy and 
inhibition of autophagy potentiates the cytotoxic efficacy of sorafenib. PC3 and 22Rv1 cells could 
further be rescued from sorafenib-induced cell death when co-cultured with cancer associated 
fibroblasts. This protection could be overcome by co-treatment with ABT737 (a Bcl-2/Bcl-xL 
inhibitor), suggesting that these anti-apoptotic proteins are, at least in part, responsible for the rescuing 
phenotype observed upon co-culture with cancer associated fibroblasts. 
In a fourth study we found that even though DU145 cells do not express ATG5 they undergo autophagy 
upon treatment with sorafenib or bafilomycin A1. Interestingly, we showed that sorafenib-induced 
autophagy in DU145 cells is cytotoxic and the cell death observed could be inhibited by the exogenous 
re-constitution of Atg5 expression. We found that treatment with molecular or chemical inhibitors of 
RIPK1 suppressed the observed cell death. Collectively our data suggest that in Atg5-deficient cells 
autophagy is cytotoxic and the ensuing cell death is executed by the necroptotic program.   
In summary, these data identify some molecular mechanisms and requirements for the successful usage 
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Cancer reminds us of chaos and anarchy, however I deeply believe that malignant cells are not 
simply impaired cells with aberrations in biological process within the body. They acquire the 
power to survive, proliferate and resist cell death intelligently. They exploit other cells to 
support them by and secreting growth factors. They can also evade the immune system 
effectively. In this chapter, I describe more about cancer, tyrosine kinase signaling in cancer 
and their inhibitors as cancer treatment.  
1.1 Cancer 
Cancer, with 26% of all deaths in 2008, is the second leading cause of death in the EU countries 
(1). Scientists estimate that our body consists of 1013 cells and any of them can potentially 
initiate a tumor. The total number of cells during a human lifetime is estimated to be about 1016 
that indicates a turnover of 10 million cells per second (2). A neoplasm can appear if any of 
these cells escape from the strict mechanisms of cell proliferation, survival or death.  
In a follow up from their landmark paper from 2000, Hanahan and Weinberg have 
complemented the six main hallmarks of cancer plus two emerging hallmarks and two enabling 
characteristics (3). 
 
1. Sustaining proliferative signaling 
One of the most important characteristics of a cancer cell is to maintain chronic proliferation 
without dependency on external growth factors (3). Normal tissues have tightly regulated 
growth that control cell growth and entry to division cycles. The majority of these growth 
factors bind to cell-surface receptors which typically contain intracellular tyrosine kinase 
domains. These domains transduce signals via signaling pathways that control cell cycle, 
growth, survival and energy metabolism. Cancer cells deregulate these signaling cascades by 
different strategies, for example prostate cancer cells can acquire an autocrine loop of vascular 
endothelial growth factor (VEGF)-VEGF receptor 2 (VEGFR2) to escape growth control (4). 
Similar mechanisms are also shown in multiple myeloma (MM) (5, 6). Another mechanism is 
activating mutations of growth factor receptors that result in continuous transduction of 
mitogenic signals to the cells. Cai et al. showed four new mutations in the epidermal growth 
factor receptor (EGFR) gene that increases cell growth and invasion of prostate cancer cell 
lines via constitutive and hyperactive tyrosine phosphorylation and cause activation of the 
mitogen-activated protein kinase (MAPK), signal transducer and activator of transcription 3 
(STAT3) and AKT pathways (7). 
 
2. Evading growth suppressors 
In addition to the ability of self-sufficiency in growth signals, cancer cells must overcome the 
signals that negatively regulate cell proliferation (3). Usually products of tumor suppressor 
genes (TSGs) are responsible for these negative feedbacks. Two of the most known examples 
of TSGs are the tumor protein 53 (TP53) and the retinoblastoma-associated (RB) proteins. RB 
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integrates extracellular and intracellular signals and determines whether or not a cell continues 
through the cell proliferation cycle. Impairment of the RB pathway, by mutations or deletion, 
leads to the loss of this critical gatekeeper of cell cycle progression, thus allowing cancer cells 
to divide continuously. The TP53 protein senses intracellular stress signals which come from 
for example excessive damage to the genome or abnormal concentrations of nucleotides, 
growth promoting signals, low glucose or oxygen. The TP53 protein temporarily pauses 
progression of the cell cycle until these stress conditions have been normalized, and if this 
cannot be achieved it activates apoptotic cell death (3). 
 
3. Resisting cell death 
A cancer cell does not only has to modify normal cellular growth pathways to grow and 
proliferate widely, but also to evade cellular death pathways (3). This acquired resistance to 
apoptosis has been shown in many types of cancers (8-11). This phenomenon is also reported 
to be involved in resistance to anti-cancer therapy. There are known mechanisms for evasion 
of cell death including: 1) disruption of the balance of pro-apoptotic and anti-apoptotic proteins 
2) reduced caspase function and 3) impaired death receptor signaling (12).  
 
4. Enabling replicative immortality 
In 1961 Leonard Hayflick showed that most normal human cells can divide between 60 to 70 
times (13, 14). This is because of shortening of telomeres at the ends of chromosomes. This 
promotes cellular senescence, a non-proliferative but viable state, or mitotic catastrophe, which 
leads to apoptosis after a certain number of cell divisions. Telomerase adds repeated segments 
of telomere to the ends of chromosomes. It is almost absent in non-immortalized cells but 
expressed in 90% of immortalized cells (2, 3).  
 
5. Development of sustained angiogenesis 
Tumors, like normal tissues, require sustained delivery of nutrients and oxygen, as well as 
removal of CO2 and metabolic byproducts. The maximal distance that oxygen, nutrients and 
waste can diffuse from or to a blood vessel is 1 to 2 millimeters and tumors cannot grow larger 
unless they induce new blood vessels, a process known as angiogenesis. Angiogenesis is 
induced at an early stage in tumor development (15). The “angiogenic switch” is controlled by 
inducers, like VEGF and hypoxia-inducible factors1 alpha (HIF-1α), and inhibitors like 
thrombospondin-1. Both hypoxia and oncogenic signaling can activate the pro-angiogenic 
switch through increased expression of VEGF or decreased degradation of HIF-1α (16). 
Malignant tumor cells also need the angiogenesis as a route for distant metastasis (13).  
 
6. Activating invasion and metastasis 
Metastasis is a complex process driven by the “invasion-metastasis cascade” and includes 
invasion through basement membranes, intravasation into blood and lymph nodes, 
extravasation and colonization of micrometastasis (17). 
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7. Reprogramming of energy metabolisms 
This emerging hallmark was first mentioned by the Nobel Prize winner Otto Warburg in 1931. 
He postulated that even in the presence of sufficient oxygen, most cancer cells predominantly 
produce energy by glycolysis rather than oxidation of pyruvate in the mitochondria (18).  
 
8. Evasion of immune system 
The second emerging hallmark is evasion from immune destruction. Tumor cells manage to 
avoid detection and destruction by immune system (3). 
 
9. Genomic instability  
Individuals who have inherited disorders in deoxyribonucleic acid (DNA) repair system that 
leads to accumulation of genetic alterations and consequently genomic instability, are more 
prone to develop cancer compared to healthy ones. Despite the diversity in genome alternation 
in different tumor type, a wide range of defects in proteins which are responsible for DNA 
maintenance and repair are known. Then genomic instability is an enabling characteristic of 
cancer cells (3).  
  
10. Tumor promoting inflammation 
For a long time it has been known that white blood cells infiltrate into tumors and it is the first 
clue of linkage between inflammation and cancer. It is known that the risk of developing cancer 
also increases in some chronic inflammatory diseases like Barrett esophagus, hepatitis B, 
chronic pancreatitis and ulcerative colitis. Inflammation plays a critical role in cancer 
development (13).  
 
1.2 Tyrosine kinase signaling in cancer 
Protein kinases catalyze the transfer of a terminal phosphate group from a nucleoside 
triphosphate (generally adenosine triphosphate (ATP)) to the hydroxyl group on a serine, 
threonine or tyrosine of a protein (19). Because of the release of a large amount of energy, this 
reaction is unidirectional. Eukaryotic kinases are named based on the amino acid modification, 
i.e. serine/threonine kinases or tyrosine kinases. This post-translational modification is reversed 
by another class of enzymes called protein phosphatases.  About 2% of the human genome 
encodes for 500 protein kinases and it signifies the importance of protein kinases in human 
biology (20). Protein kinase can modify up to 30% of all human proteins and they are involved 
in the regulation of cellular pathways, especially those involved in signal transduction and 
regulating cellular activity (21). Tyrosine kinases are classified into two subgroup: Non-
receptor tyrosine kinase (NRTK) and receptor tyrosine kinase (RTK).  
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1.2.1 Non-receptor tyrosine kinase 
So far around 32 non-receptor tyrosine kinases have been identified in human cells (22). Non-
receptor tyrosine kinases are involved in a variety of signaling processes, including T- and B-
cell activation, mitogenesis, cytoskeleton restructuring, differentiation, adhesion, migration 
and cell death (23, 24).  
The majority of the NRTKs are cytoplasmic enzymes but some of them are found attached to 
the cell membrane by amino acid modifications like myristoylation or palmitoylation and some 
of them, like Abelson murine leukemia viral oncogene homolog (ABL) and Feline sarcoma-
related (FER), are found in the nucleus (25, 26). They have a modular structure which 
comprises of several domains which bind to each other. Apart from the tyrosine kinase domain 
they contain protein-protein, protein-lipid, and protein-DNA interaction domains. Src 
homology 2 (SH2) and Src homology 3 (SH3) domains are the most common protein-protein 
interaction domains in this family which enable them to interact with both upstream and 
downstream signaling molecules (27). A hundred amino acid constitute the SH2 domain that 
binds to phosphotyrosine and the SH3 domain is composed by 60 amino acid and makes a 
polyproline type II helix. Pleckstrin homology (PH) domain binds to phosphatidylinositol 
(PtdIns) lipids, which are found in the plasma membrane and can lead to the activation of the 
Phosphatidylinositol 4,5-bisphosphate 3-kinase (PI3K) pathway. Janus kinase (JAK) 
homology domains target JAK family protein to the cytoplasmic part of cytokine receptors. 
Integrin-binding- and a focal adhesion-binding domains are two other examples of protein-
protein interaction domains. Other examples are the DNA-binding domain and F actin–binding 
domain, two domains which are found in for instance in ABL (23). 
It is possible to classify NRTKs based on structural similarities into several families: ABL, C-
terminal Src kinase (CSK), focal adhesion kinase (FAK), feline sarcoma oncogene/fujinami 
avian sarcoma viral oncogene homolog (FES), Janus kinase (JAK), Src, spleen tyrosine kinase 
(SYK), Tec protein kinase (Tec), tyrosine kinase nonreceptor (TnK) (28). 
 Src Family: Src is the prototype of the Src protein tyrosine kinase family members, 
and it contains several proteins like B-cell lymphocyte kinase (Blk), hemopoietic cell 
kinase (Hck) and Src (28). Src has dual functions, as a scaffold molecule to assemble 
signaling complexes and as a tyrosine kinase. Src family members anchor to the cell 
membrane through the N-terminal region whereas the SH3, SH2 and kinase regions in 
C-terminal which contains two critical tyrosine residues (Tyr-416 and Tyr-527) that 
regulate the Src activity (29). The phosphorylated Tyr-527 at the C-terminal interacts 
with the SH2 domain which folds Src to a closed bundle. Tyrosine phosphatases 
dephosphorylate Tyr-527 and opens up inactive Src. Various tyrosine kinases 
phosphorylate Src on the Tyr-416 which is located within the kinase domain, resulting 
in an increase in enzyme activity. Some proteins like PDFG and FAK can bind to the 
SH2 domain and activate Src (30). This can be achieved by either direct contact 
between Src and its potential substrate or relocalization of Src inside the cell to have 
close proximity to potential substrate (31). Active Src has been shown to promote 
survival, proliferation, angiogenesis and invasion pathways (32). Src can also activate 
downstream tyrosine kinases such as ABL (33) or promote formation of the osteoclast 
podosome with proline-rich tyrosine kinase 2 (Pyk2) (34).  
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 CSK: CSK can phosphorylate Tyr-527 in the Src family and inactivate them (35, 36). 
 ABL: ABL is an oncogene which is required for the development of leukemia’s and its 
expression is induced by chromosome translocations or retroviruses (37). ABL1 and 
ABL2 are two members of ABL family that transduces extracellular signals which 
control proliferation, survival, migration, cellular polarity and invasion. ABL kinases 
are activated in breast-, lung-, colorectal-, gastric-, prostate cancer and melanoma cells. 
 FAK: FAK was identified as a substrate for viral Src in 1992 and it controls cell 
motility (38). FAK does not contain SH2 or SH3 protein interaction domains. FAK is 
activated by growth factors and integrins during migration and recruits other focal 
contact proteins or their regulators to facilitate cellular movement. FAK transduces 
signal from growth factor- and integrin receptors to extracellular the signal-regulated 
kinase 2 (ERK2)/MAPK cascade and Rho family GTPases (38, 39). 
 FES: The structure of FES consists of an N-terminal FCH (FES/FER/ Cdc42-
interacting protein 4 (CIP4) Homology) domain, three coiled-coils regions, an SH2 
domain and a C-terminal kinase domain. FES play a role in cell-cell and cell-matrix 
interactions (40). 
 JAK: JAKs are involved in the regulation of several cellular functions including cell 
proliferation, differentiation, cell migration and apoptosis (41). In mammals, the JAK 
family comprises four members: JAK1, JAK2, JAK 3 and Tyrosine kinase 2 (Tyk2). 
Erythropoietin, growth hormone, interferons and interleukins bind to their receptors, 
where erythropoietin and growth hormone receptos homodimerize and interferon and 
interleukin receptos heterdimerize and as the result two JAKs which are bound to the 
cytoplasmic domain of these receptors phosphorylate each other and subsequently 
phosphorylate the receptors. These phosphorylated parts act as docking sites for the 
SH2 domains for STATs. Then STATs are phosphorylated by the JAKs and make 
homo- or heterodimers and translocate to the nucleus. The STAT dimers bind to the 
STAT responsive element in the promoter through their DNA-binding domains and 
repress or activate or transcription of target genes. The JAK/STAT signaling cascade 
thus facilitates the transduction of an extracellular signal to a transcriptional response 
(41-43). 
 SYK: SYK plays a role in adaptive immune receptor signaling, cellular adhesion, 
innate immune recognition, osteoclast maturation, platelet activation and vascular 
development (44). 
 Tec: Members of the Tec kinase family are the second largest class of NRTK. They 
participate in lymphocyte development and activation(45). 
 Tnk: Tnk are involved in cell survival, tumor development and migration (46). 
 
1.2.2 Receptor tyrosine kinase 
In 1952 Rita Levi-Montalcini discovered the nerve growth factor (NGF) (47). She showed that 
NGF extracted from mouse tumors, can promote neurite outgrowth in chicken embryos. 
Stanley Cohen isolated and characterized epidermal growth factor (EGF). They won the Nobel 
Prize in Physiology or Medicine in 1986 for their work. Cohen and his colleagues also 
discovered the EGFR in 1978 (47). Now 58 RTKs are known in human which are categorized 
into 20 families (Figure 1) (48, 49). All RTKs have a similar molecular structure. An 
extracellular region which binds ligand, a single transmembrane helix and an intracellular 
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region which contains juxtamembrane regulatory region and tyrosine kinase domain (49). 
When growth factors bind to the RTKs, usually two RTK monomers dimerize. Some RTKs 
like Insulin-like growth factor 1 (IGF1) exist as oligomers in absence of its ligand. Binding of 
insulin induces conformational changes in the structure of the receptor dimer, which activates 
its kinase activity by autophosphorylation (50). After dimerization, the activated receptor 
phosphorylates tyrosines in adjacent RTK and the phosphorylated receptor activates or 
assembles intracellular signaling proteins (49). From here on, I will focus on the RTKs that are 




Figure 1. Human receptor protein-tyrosine kinases. The prototypic receptor for each family is 
indicated above the receptor, and the known members are listed below. Reproduced with permission 
from Oncogenic kinase signaling, Peter Blume-Jensen and Tony Hunter, Nature 411, 355-365. 
 VEGFR: VEGFR comprises three receptors, VEGFR-1 (fms-related tyrosine kinase 
1(Flt-1)), VEGFR-2 (kinase insert domain-containing receptor (KDR) / Fetal Liver 
Kinase 1 (Flk-1)) and VEGFR-3 (Flt-4) (51). VEGF is the ligand for VEGFR. The 
VEGF-A gene is located on the short arm of chromosome 6 and consists of eight exons 
and seven introns and alternative exon splicing generates four different VEGF isoforms 
(52). VEGF belongs to the platelet-derived growth factor (PDGF) superfamily and it is 
a heparin-binding homodimeric glycoprotein (53). VEGF can promote endothelial cell 
survival and vascular permeability through activation of PI3K/AKT, endothelial cell 
migration through activation of p38 MAPK and endothelial cell proliferation through 
activation of the Ras/Raf/MEK/ERK signaling pathway (51). 
 FGFR: This family of tyrosine kinase includes the 4 receptor fibroblast growth factor 
receptors (FGFR1, FGFR2, FGFR3, and FGFR4) with 18 known ligands that can bind 
to them and transfer extracellular signaling into the cytoplasm through tyrosine kinase 
signaling (54). Several examples are known relating to cancer development due to 
dysregulation of FGFR signaling such as activating mutations found in 50% of bladder 
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cancer cases (55), prostate cancer and multiple myeloma (54), FGFR gene 
amplifications, a rare event associated with gastric-, lung- and breast cancer (56), 
chromosomal translocation, is frequently found in multiple myeloma (57) and 
increased autocrine and paracrine signaling, observed in melanoma and prostate cancer 
(54, 58). Deregulated FGF signaling can increase the activity of downstream signaling 
cascades which lead to tumorigenesis. For example in T cell lymphoma, the ets variant 
6 (ETV6)-FGFR3 fusion protein activates PI3K signaling (59). Fibroblast growth 
factor (FGF) can also promote resistance to apoptosis by inducing the expression of 
anti-apoptotic proteins through PI3K/AKT and STAT signaling. It has been shown that 
FGF can induce the expression of B-cell lymphoma 2 (BCL-2), B-cell lymphoma extra-
large (Bcl-xL), X-linked inhibitor of apoptosis protein (XIAP) and inhibitor of 
apoptosis family of proteins 1 (IAP1). FGF can induce proliferation and decrease 
apoptosis by MAPK signaling (54). In bladder cancer and multiple myeloma, the FGFR 
has been shown to activate the nuclear factor kappa B (NFκB) signaling pathway 
responsible for proliferation, survival and anti-apoptotic effects (60). It is also shown 
that FGFR activation can lead to increased invasion and angiogenesis (61).  
 PDFGR: This family consists of PDGF receptor α and , stem cell factor receptor (c-
Kit), colony-stimulating factor- 1 (CSF-1) receptor, and Flt-3 (62). They are composed 
by five Ig-like domains in their extracellular part, a transmembrane domain, an 
intracellular juxtamembrane domain, a tyrosine kinase domain and a C-terminal tail. 
Their ligands are dimeric and induce receptor dimerization upon binding. The PDGFR 
family has two members, PDGFRα and PDGFRβ. PDGF is the ligand for PDGFR and 
it exists in both disulphide-bonded homodimer forms (PDGF-AA, -BB, -CC, -DD) and 
heterodimer form PDGF-AB. The Monomeric form of PDGF is inactive. Upon binding 
of the PDGF dimer to PDGFR, two PDGFRs dimerize and make several possible 
combinations; PDGFR-αα, -ββ and –αβ. All these receptors can be activated by PDGF-
BB (63-65). Oncogenic activation of PDGFR includes: 1.chromosomal rearrangement: 
Increased expression of PDGFR after fusion with the gene encoding collagen 1A1 in 
dermatofibrosarcoma protuberance (DFSP) and constitutive activation of  PDGFRα 
after rearrangement with FIP1L1 in chronic myelomonocytic leukemia, haves been 
reported leukemia (63, 66); 2. Point mutation: It has been demonstrated that point 
mutations in exon 9 or 11 of PDGFRα gene cause constitutive kinase activation of the 
PDGFRα by disrupting regulatory portions of PDGFRα which are fundamental in 
gastrointestinal stromal tumors (GIST) development (67). The PDGFRs can transduce 
the extracellular signal through downstream signaling like PI3K, STAT and 
Ras/Raf/MEK/ERK signaling pathways (64). 
 c-Kit receptor: Following dimerization of the c-Kit receptor (CD117) by binding of 
dimeric ligands, PI3K/AKT, Src kinases, Ras/Raf/ERK pathway and phospholipase C 
and D can be activated and regulate cellular proliferation, differentiation and migration, 
tumor  development and recurrence (62). Alterations in the c-Kit receptor is involved 
in pathogenesis or progression of acute myeloid leukemia, GIST, mastocytosis 
melanoma and small-cell lung cancer (SCLC) (62, 68).  
 Flt3: Flt3 is expressed only in cells with high level of the CD34 antigen like early 
progenitors of hematopoiesis, B-lymphoid progenitor cells and monocytes (69). A 
mutation of the Flt3 gene which leads to the expression of a constitutively active 
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receptor was found in acute myeloid leukemia (AML) and acute lymphoblastic 
leukemia (ALL). PI3K/AKT and Ras/Raf/ERK signaling pathways are activated by 
Flt3 and this promotes cell mobilization, proliferation and survival (69, 70). 
 IGFR: The IGF system consist of two tyrosine kinase receptors, the insulin receptor 
(IR) and the IGF-1 receptor (IGF-1R), and insulin receptor-related protein (InsRR) 
which are activated upon binding of four different ligands (insulin, proinsulin, IGF-I 
and IGF-II) and six regulatory binding protein (IGFBP1 - IGF-BP6) (71). The IGFBPs 
are transport proteins for IGF-I and IGF-II in the circulation and also regulate their 
access to the IGF-1R. Free IGF has a very short half-life while the bound fraction has 
a longer half life (72). There are many common effects of insulin and IGF-1 like 
stimulation of cell proliferation, glucose uptake and protein synthesis, decreased fat 
breakdown, induction of DNA and RNA synthesis and inhibition of apoptosis (73). The 
two main signaling pathways downstream of the IGFRs are the PI3K/AKT and 
Ras/Raf/MEK/ERK pathways which are coupled to IGFR through the insulin receptor 
substrate (IRS) and Src homology 2 domain containing transforming protein 1 (Shc) 
protein, respectively (71, 74). It has been shown that the IGF system is involved in the 
pathogenesis, progression and metastasis of breast-, prostate- and colon cancer (75). 
 Ret: The REarranged during Transfection (RET) proto-oncogene encodes for the RET 
protein which is associated with papillary thyroid carcinoma (76). The RET receptor 
has four extracellular cadherin-like domains, the cysteine-rich region and tyrosine 
kinase domains. It has isoforms, RET9 and RET51 which is an anchoring site for 
docking proteins. Consequently these proteins can activate multiple signaling 
pathways, including the PI3K/AKT, Ras/Raf/ERK and Rac/c-jun NH kinase (JNK). 
Through these signaling pathways, the RET receptor plays a role in cellular motility, 
proliferation, differentiation and survival (77). 
 
 
1.2.3 Downstream signaling cascades 
1.2.3.1 The PI3K/AKT signaling pathway:  
The class I phosphatidylinositol 3-kinases (PI3Ks) is the most extensively investigated family 
of the three different classes of PI3Ks and it can be divided into Class IA PI3Ks which are 
activated by receptor tyrosine kinases and class IB PI3Ks which are activated by G-protein-
coupled receptors (GPCRs) (78, 79). Class IA PI3Ks are composed of three isoforms of the 
p110 catalytic subunit (p110α, β and δ) and three isoforms of the p85 (p85 α, β and δ) regulatory 
subunit (Figure 2) (78). Phosphatidylinositol, phosphatidylinositol-4-phosphate (PIP), and 
phosphatidylinositol-4, 5-bisphosphate (PIP2) are substrates of Class IA PI3Ks. Class IB 
PI3Ks consist of the p110γ catalytic subunit and a p101 regulatory subunit or its homologues 
p84 or PI3Kγ adaptor protein of 87 kDa (p87PIKAP) (80).  
Binding of ligand to RTKs leads to the phosphorylation of the C-terminal tail of RTK allowing 
for the recruitment of the inactive p85-p110 complex to the receptor. The catalytic subunit of 
p110 is thus brought in close proximity to its lipid substrates in the plasma membrane. The 
inhibition of p85 on p110 kinase can be relieved by the RTK-p85 interaction which induces 
conformational changes in p85-p110 complex. Ras is another important signaling molecule, 
activated downstream of RTKs and which promotes the activation of the p110 subunit. 
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Phosphatidylinositol 3-kinase (PI3K) phosphorylates PtdIns (4,5)P2 (PIP2) to form the second 
messenger PtdIns (3,4,5)P3 (PIP3). PIP3 can be dephosphorylated by PTEN. Generation of 
PIP3s in the plasma membrane leads to the recruitment of AKT and its upstream activator 3-
phosphoinositide-dependent protein kinase-1 (PDK1) which phosphorylates AKT on Thr308 
and activates it.  PDK2 can phosphorylate AKT at Ser473 (78). In general, AKT activation has 
three main downstream effects:  
 Cell survival: Activated AKT inhibits apoptosis by several mechanisms (78, 81); 1) first 
AKT phosphorylates Bcl-2-associated death promoter (BAD) protein, a pro-apoptotic 
member of BCL2 family. BAD can make a heterodimer with the anti-apoptotic survival 
factor Bcl-xL but phosphorylated BAD cannot interact with Bcl-xL. 2) AKT also 
phosphorylates and inactivates caspase-9; 3) AKT can phosphorylate and activate IκB 
kinase (IKK) followed by degradation of this NFκB inhibitor, which leads to the activation 
of the NFκB survival pathway; 4) AKT can phosphorylate mouse double minute 2 homolog 
(MDM2) which leads to enhanced degradation of the pro-apoptotic tumor suppressor 53. 
 Cell proliferation: AKT promotes cell proliferation by affecting cell-cycle machinery 
(82). p21 is an protein which can make complex with proliferating cell nuclear antigen 
(PCNA) and inhibit DNA replication. p21 is also binds to Cdk2 and inhibit cell cycle 
progression. It mainly inhibits the activity of cdk2 complexes and negatively modulates 
cell cycle progression. AKT phosphorylates the p21 at Thr145 and it has two effects, first 
it prevents the complex formation of p21 with PCNA and second decrease of binding of 
p21 to Cdk2. These effects promote cell cycle progression (83). 
 Cell growth: The mammalian target of rapamycin (mTOR), a serine/threonine kinase, is a 
central regulator of cell growth and its activity regulated by AKT (78). mTOR is part of 
two complexes, mTOR complex 1(mTORC1) and mTORC2 which can be stimulated by 
interleukin 6 (IL-6), insulin and other growth factors. mTORC1 consist of mTOR, 
regulatory-associated protein of mTOR (Raptor), mammalian lethal with SEC13 protein 8 
(mLST8), proline-rich AKT1 substrate 1 40 (PRAS40) and DEP domain-containing 
mTOR-interacting protein (DEPTOR). Tuberous sclerosis 1 (TSC1) and TSC2 are negative 
regulators of the mTOR activity. AKT can phosphorylate TSC2 followed by dissociation 
of the TSC1/2 complex from mTORC1, leading to its activation. AKT can also 
phosphorylate and inactivate PRAS40 which is a negative regulator of mTORC1. In 
addition, activated AKT increases the expression of amino acid and nutrient transporters 
like Glucose transporter 1 (Glut1) in the cell membrane leading to the activation of 
mTORC1. On the other hand mTOR can also activate AKT via mTORC2. The mTORC2 
components include mTOR, rapamycin insensitive companion of mTOR (Rictor), 
mammalian stress-activated protein kinase -interacting protein (mSIN1), PROTOR-1, 
DEPTOR and mLST8 which regulate Protein kinase C alpha (PKC-α), Serum- and 
glucocorticoid-regulated kinase (SGK) and AKT. mTOR has been involved in sensing ATP 
level (78, 84-87). 
Under basal physiological conditions, inactive p70 S6 kinase makes a complex with 
eukaryotic initiation factor 3 (eIF3) (88). After growth factor stimulation, mTORC1 binds 
to the eIF3-S6K complex and detaches S6K from the mTORC1-eIF3 complex. mTORC1-
eIF3 complex associates with the 5’mRNA cap structure. Interaction between the scaffold 
protein eIF-4G with eIF-4F, eIF-4A and polyA binding protein (PABPC) makes up the 
cap-structure on mRNAs and initiates protein synthesis. The hypophosphorylated form of 
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4E-BP1 is attached to eIF-4E and inhibits the interactions of eIF-4G with eIF-4E. The 
phosphorylation of 4E-BP1 occurs sequentially at the Thr37 and Thr47, Ser65 and Thr70 
leading to gradually enhanced activation of translation. 
 
Figure 2. PI3K/AKT signaling pathway. Reproduced with permission from The phosphatidylinositol 3-
Kinase–AKT pathway in human cancer, Igor Vivanco & Charles L. Sawyers, Nature Reviews Cancer 2, 489-501 
 
1.2.3.2 The MAPK signaling cascade:  
This signaling pathway consist of four family members p38, c-jun-N-terminal kinase (JNK), 
Extracellular signal-regulated kinase 1/2 (ERK 1/2) and ERK5 (89).  
 
Ras/Raf/MEK/ERK:  
Activation of some RTKs like PDGFR, VEGFR and FGFR causes binding of growth-factor-
receptor-bound protein 2 (GRB2) to the cytoplasmic tails of the receptor (Figure 3) (89). Then 
the guanine-nucleotide exchange factor SOS docks to GRB2 and this complex replaces GDP 
with GTP- (in Ras) and activates Ras. Ras induces the kinase activity of Raf which 
phosphorylates and activates the mitogen-activated protein kinase kinase (MEK) by 
phosphorylation on two serine residues, Ser217 and Ser221. MEK has two isoform MEK1 and 
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MEK2. MAPK/extracellular signal-regulated kinase 1 (ERK1) is phosphorylated on Thr202 
and Tyr204 and ERK2 is phosphorylated on Thr185 and Tyr187 by active MEK1/2. Active 
ERK1/2 has several cellular downstream effects like activation of several downstream kinases 
and activation of transcription factors including the peroxisome-proliferator-activated receptor-
gamma (PPAR γ), ETS domain-containing protein (ELK1), ETS, signal transducer and 
activator of transcription 1 (STAT1) and STAT3. The overall effect of Ras/Raf/MEK/ERK 
activation is cell cycle progression and increase in cell motility. 
AKT and SGK are furthermore negative- and PKC, SRC, p21-activated kinase (PAK), 14-3-3, 
adhesion of integrins to extracellular-matrix molecules positive inducers of this signaling 
pathway (89-91). 
 
Figure 3. Ras/Raf/MEK/ERK pathway. Reproduced with permission from The clinical development of 
MEK inhibitors, Yujie Zhao& Alex A. Adjei, Nature Reviews Clinical Oncology, 11, 385–400 (2014). 
 
1.3 Tyrosine kinase inhibitors in cancer treatment 
1.3.1 Overview 
Tyrosine kinase activity deregulation is widely observed in various cancer types thus making 
these kinases a suitable target for anticancer therapy.  
There are three approaches to target tyrosine kinases:  
1. Prevent the interaction between ligand and its receptor(s) by targeting the growth factors 
before binding to their receptor(s). One example is bevacizumab, a Food and Drug 
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Administration (FDA) approved humanized neutralizing immunoglobulin G1 against VEGF 
that inhibits the binding of VEGF to VEGFRs (92).  
2. Prevent the interaction between ligand and its receptor by targeting the extracellular domain 
of RTKs. Trastuzumab is an example of a monoclonal antibody which targets the extracellular 
domain of the human EGFR2 (human epidermal growth factor receptor 2 (HER2 or ErbB-2)) 
protein (93). 
3. Target the intracellular domain of RTKs. The majority RTK inhibitors (RTKis) belong to 
this approach and they are classified into four categories: Type I inhibitors, recognize the active 
conformation of the kinase and bind in and around the region occupied by the adenine ring of 
ATP (94, 95); Type II inhibitors occupy a hydrophobic site that is directly adjacent to the ATP 
binding pocket leading to an alteration in the conformation of the activation loop known as 
DFG-out. The type II RTKi recognize the inactive conformation of the kinases (94, 95); Type 
III inhibitors are capable of inhibiting RTKs in an allosteric manner, binding at an allosteric 
site which is located outside the ATP-binding site. This group has the highest degree of kinase 
selectivity. CI-1040, the inhibitor of MEK1 and MEK2, belongs to this group (95); Type IV 
inhibitors are covalent inhibitors. Usually they make an irreversible covalent bond with a 
cysteine residue in the kinase active site. HKI-272, an EGFR inhibitor, is one example of such 
a covalent inhibitor (96). 
 
1.3.2 Sorafenib 
Bayer and Onyx initiated a collaboration to discover new agents to target the 
Ras/Raf/MEK/ERK pathway. High-throughput screening for Raf1 kinase inhibitory activity 
led to identification of sorafenib (BAY 43-9006, Nexavar®) (Figure 4) (97). Sorafenib is 
available as tablets made by Bayer under trade name of Nexavar®. Each tablet contains 
sorafenib tosylate (274 mg) equivalent to 200 mg of sorafenib (98). 
The recommended dose of sorafenib is 400 mg orally twice daily. Treatment should continue 
until there are no clinical benefits or toxicity occurs. In the case of adverse reactions, the dosage 
can be reduced to 400 mg per day or 400 mg per every other day (99). 
The empirical formula of sorafenib tosylate is C21H16ClF3N4O3 x C7H8O3S. 
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Figure 4. Cellular targets of sorafenib. Reproduced with permission from Discovery and development of 
sorafenib: a multikinase inhibitor for treating cancer. Scott Wilhelm, Christopher Carter, Mark Lynch, Timothy 
Lowinger, Jacques Dumas, Roger A. Smith, Brian Schwartz, Ronit Simantov & Susan Kelley, Nature Reviews 
Drug Discovery 5, 835-844 (October 2006). 
 
1.3.2.1 Pharmacological actions: 
Sorafenib is a type II inhibitor of Raf-1 (C-Raf), B-Raf, V600E B-Raf, VEGFRs, PDGFRβ, 
FGFR1, c-Kit, Flt-3 and RET (97). Sorafenib cannot inhibit MEK1, ERK1, protein kinase B, 
protein kinase A, protein kinase Cα, protein kinase-Cγ, EGFR, HER2/neu and IGFR1 (97, 100, 
101).  
Apart from targeting tyrosine and serine/threonine kinases, sorafenib has also been shown to 
modulate the protein stability of complex I components of the mitochondrial electron transport 
chain leading to loss of mitochondrial membrane potential and caspase- independent cell death 
(102). 
Sorafenib can also induce apoptotic cell death via a mitochondria-dependent oxidative stress 
mechanism. Sorafenib induces rapid production of reactive oxygen species (ROS) which leads 
to the depletion of intracellular glutathione. This effect is independent of the kinase inhibition 
capacity of sorafenib (103). 
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1.2.3.2 Indications 
Currently sorafenib is FDA approved for three indications (104). On December 20, 2005, the 
FDA approved sorafenib tosylate for the treatment of patients with advanced renal cell 
carcinoma (RCC) and on November 16, 2007 for the treatment of patients with unresectable 
hepatocellular carcinoma (HCC) and finally for the treatment of locally recurrent or metastatic, 
progressive differentiated thyroid carcinoma (DTC) refractory to radioactive iodine treatment 
on November 22, 2013. 
 
1.2.3.3 Pharmacokinetics 
Sorafenib reaches the peak of plasma levels in three hours following oral administration with 
a mean elimination half-life of approximately 25-48 hours (98). The mean bioavailability of 
oral sorafenib is 38-49%. Bioavailability of sorafenib is reduced by 29% when consumed with 
a high-fat meal. Steady state for plasma concentrations of sorafenib are reached within 7 days. 
Almost 99.5% of sorafenib binds to human plasma protein (98, 105). Sorafenib is metabolized 
by two metabolic pathways in the liver and kidney. Cytochrome P450 3A4 (CYP3A4) (M2) 
oxidizes the pyridine N-oxide ring of sorafenib and UDP glucuronosyltransferase 1(UGT1A9) 
(M7) conjugates sorafenib with glucuronic acid. Seventy seven percent of the administrated 
sorafenib dose is excreted in feces (50% as unchanged drug) and 19% in urine as glucuronide 
conjugates (106).  
 
1.2.3.4 Toxicity 
The most notable acute adverse events related to sorafenib include asthenia (weakness), rashes 
and hand-foot skin reaction (HFSR), diarrhea and arterial hypertension (107). The other 
frequent adverse reactions to sorafenib are infection, lymphopenia, anorexia, 
hypophosphatemia, hemorrhage,  nausea, vomiting, constipation, dry skin, alopecia, arthralgia, 
pain, fever, weight loss, increased amylase and increased lipase (107). 
The mechanisms underlying the adverse effects of sorafenib are not clear but it has been 
postulated that VEGFR inhibition is responsible for hypertension and hypothyroidism, and skin 
toxicity is caused because of secretion of sorafenib by the eccrine glands of the skin (96). 
 
1.2.3.5 Sorafenib in cancer treatment 
Based on registered data (https://clinicaltrials.gov) on 2014-08-04, there are 638 clinical trials 
with sorafenib, out of which 10 trials are in phase IV, 68 in phase III, 358 in phase II, 199 in 
phase I, 1 in phase 0 and 2 of them not mentioned. All phase IV clinical trials are in patients 
with hepatocellular- or renal cell carcinoma. Sorafenib as an anticancer treatment is in phase 3 
trials in cancers like hepatocellular carcinoma, renal cell carcinoma, non-small cell lung cancer 
(NSCLC), acute myeloid leukemia, desmoid tumors or aggressive fibromatosis, melanoma, 
thyroid, breast and pancreatic cancer. 
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1.2.3.5.1 Sorafenib in multiple myeloma treatment 
In a panel of human myeloma cell lines we have found responsiveness to sorafenib which we 
further showed similar efficiency in an in vivo mouse model as well as freshly isolated CD138+ 
multiple myeloma cells from newly diagnosed patients (108). Ramakrishnan and colleagues 
have also investigated the effect of sorafenib in multiple myeloma and they reported that 
sorafenib is toxic for both cell lines and patient samples (109). Udi and colleagues have also 
reported that sorafenib induces apoptosis in myeloma cell lines (110). It reduces CD138-
expression and induces actin depolymerization in these cell lines, which can disrupt the 
microenvironment support of tumor cells. Another recent study depicts induction of caspase-
dependent apoptosis in myeloma cell lines and patient samples treated with sorafenib. They 
have also shown in the MM.1S cell line, that co-treatment of sorafenib with the pan caspase 
inhibitor Z-VAD-fmk induces necroptosis (111). 
Seven clinical trials using sorafenib in myeloma are ongoing as follows: 
1. “A phase I/II study of the Raf kinase/VEGFR inhibitor sorafenib in combination with the 
mTOR inhibitor RAD001 (Everolimus) in patients with relapsed non-Hodgkin lymphoma, 
Hodgkin lymphoma, or multiple myeloma”, ClinicalTrials.gov identifier: NCT00474929. 
This study is ongoing, but not recruiting participants. 
 
2. “Phase I/II trial of sorafenib and weekly Bortezomib in the treatment of patients with 
relapsed or refractory multiple myeloma”, ClinicalTrials.gov identifier: NCT00536575. 
This study is ongoing, but not recruiting participants. 
 
3. “Phase I/II study of sorafenib, Lenalidomide, and Dexamethasone in relapsed/refractory 
multiple myeloma”, ClinicalTrials.gov identifier: NCT00687674. Due to study design and 
toxicity, this study has been terminated. 
 
4. “A Phase II trial of BAY 43-9006 (sorafenib) (NSC-724772) in patients with relapsing or 
resistant multiple myeloma”, ClinicalTrials.gov identifier: NCT00253578. This study has 
been completed. 
In this latter investigation, the researchers looked for overall response rate in patients with 
a confirmed diagnosis of refractory or relapsed (RR) multiple myeloma (MM) with 
measurable monoclonal protein. Patients were treated with 400 mg oral sorafenib twice a 
day for 28-day treatment cycles. Three of eighteen eligible patients experienced grade 4 
toxicities: one with thrombocytopenia, one with anemia, and one with renal failure. Four 
of the eighteen eligible patients were removed from study because of toxicity in three 
patients and one for personal reason. No partial or complete responses were observed in 
this study and authors suggested combination therapy of sorafenib with standard 
medications (112). 
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5. “Pharmacokinetic and phase I study of sorafenib (BAY 43-9006, NSC 724772, IND 69896) 
for solid tumors and hematologic malignancies in patients with hepatic or renal 
dysfunction”, ClinicalTrials.gov identifier: NCT00118170. This study has been completed. 
 
6. “A phase I study of the Raf Kinase/VEGFR inhibitor BAY 43-9006 in combination with 
the proteasome inhibitor PS-341 in patients with advanced malignancies”, 
ClinicalTrials.gov identifier: NCT00303797. This study has been completed. 
Three renal, three lung, two pancreatic cancer and one patient from each of the following 
cancer type, breast, adrenal gland, melanoma, spindle cell tumor, chronic lymphocytic 
leukemia and multiple myeloma were enrolled to this study to define the toxicity and the 
maximum tolerated doses of the combination of sorafenib and bortezomib. The author 
concluded that the combination of sorafenib and bortezomib was well tolerated (113).  
 
7. “A phase I study of Lenalidomide in combination with Bevacizumab, sorafenib, 
Temsirolimus, or 5-fluorouracil, Leucovorin, Oxaliplatin (FOLFOX) in patients with 
advanced cancers”, ClinicalTrials.gov identifier: NCT01183663. This study is ongoing, but 
not recruiting participants. 
 
1.2.3.5.2 Sorafenib in prostate cancer treatment: 
We demonstrated that sorafenib induces cell death in both hormone refractory and hormone 
responsive prostate cancer cell lines. Sorafenib also decreases ERK phosphorylation and 
induces autophagy in these cells (114). We have also analyzed sorafenib induced cell death in 
greater detail in some prostate cancer cell lines (115). Huang and colleagues have reported that 
sorafenib decreases ERK phosphorylation and mitochondrial depolarization in prostate cancer 
cell lines (116). They also showed sorafenib induces cytochrome c release from mitochondria 
and caspase 3 activation. In another study the effect of sorafenib on rats that were inoculated 
with the prostate carcinoma cell line MLLB-2 was investigated. The authors showed that 
treatment with 10 mg per kg of sorafenib via gastric gavage reduces number of endothelial and 
proliferating cells and induced the number of apoptotic cells (117-119). Su and colleagues 
showed that sorafenib induces apoptosis in both androgen receptor positive and negative 
prostate cancer cells. It causes downregulation of the anti-apoptotic protein myeloid leukemia 
cell 1 (Mcl-1) and AKT phosphorylation. Sorafenib also decrease expression of androgen 
receptor and PSA levels in androgen-sensitive cell lines (120). 
Current clinical trials regarding of administrating of sorafenib in prostate cancer are: 
1. “A phase II study of sorafenib (Nexavar®) prior to radical prostatectomy in patients with 
high-risk localized prostate cancer”, ClinicalTrials.gov Identifier: NCT00466752.This 
study has been completed. 
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2. “A phase II study of BAY 43-9006 (sorafenib) in metastatic, androgen-independent 
prostate cancer”, ClinicalTrials.gov Identifier: NCT00090545. This study has been 
completed and were published. The authors reported that sorafenib is relatively well 
tolerated in androgen independent prostate cancer patients (121) and shows moderate 
activity in treatment for metastatic castration-resistant prostate cancer (122). 
 
3. “Phase I/II study of sorafenib concurrent with androgen deprivation and radiotherapy in the 
treatment of intermediate- and high-risk localized prostate cancer”, ClinicalTrials.gov 
Identifier: NCT00924807, This study has been terminated by sponsor.  
 
4. “Phase II study of sorafenib (Bay 43-9006) and Docetaxel in metastatic prostate cancer”, 
ClinicalTrials.gov Identifier: NCT00619996, This study has been completed. 
 
5. “Open-label, multicenter, phase I trial in order to determine the safety and 
pharmacokinetics of BAY43-9006 in combination with Docetaxel as first-line treatment in 
metastatic hormone refractory prostate cancer patients”, ClinicalTrials.gov Identifier: 
NCT00405210, This study has been completed. In this study, the researchers increased the 
dose of sorafenib and combined it with Docetaxel and prednisone. They concluded that 400 
mg sorafenib twice per day can be combined with Docetaxel and prednisone (123). 
 
6. “Mitoxantrone, Prednisone plus sorafenib in Taxane-refractory metastatic hormone 
refractory prostate cancer (HRPC)”, ClinicalTrials.gov Identifier: NCT00452387, This 
study has been terminated due to early stopping rule. 
 
7. “A phase II study of BAY 43-9006 (NSC 724772; CTEP IND# 69,896) in patients with 
hormone refractory prostate cancer”, ClinicalTrials.gov Identifier:NCT00093457,This 
study has been completed. In this study patients with a pathologic diagnosis of 
adenocarcinoma of prostate and PSA equal or higher than 10 μg/l have been received 400 
mg sorafenib twice daily continuously for 4 weeks. Twenty eight patients were enrolled 
and PSA was decreased in one patients more than 50% and in five patients less than 50 
percent. The authors concluded that sorafenib has limited activity regarding PSA as an 
indicator of response to treatment (124). 
 
8. “Phase I study investigating the safety and feasibility of combining Imatinib Mesylate 
(Gleevec) with sorafenib in patients with androgen-independent chemotherapy-failure 
prostate cancer”, ClinicalTrials.gov Identifier: NCT00424385, This study has been 
completed. 
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9. “Phase I/II study to evaluate the ability of sorafenib in overcoming resistance to systemic 
chemotherapy in androgen-independent prostate cancer (AIPC)”, ClinicalTrials.gov 
Identifier: NCT00414388, This study has been completed. 
 
10. “A Phase II study of BAY 43-9006 in combination with Bicalutamide in patients with 
chemo-naïve hormone refractory prostate cancer”, ClinicalTrials.gov Identifier: 
NCT00430235.This study has been completed. 
 
11. “Phase I study of sorafenib, Pemetrexed, and Cisplatin for the treatment of advanced solid 
tumors”, ClinicalTrials.gov Identifier: NCT00703638.This study has been completed. 
 
12. “A Phase I study of Lenalidomide in combination With Bevacizumab, sorafenib, 
Temsirolimus, or 5-fluorouracil, Leucovorin, Oxaliplatin (FOLFOX) in patients with 
advanced cancers” , ClinicalTrials.gov Identifier: NCT01183663, This study is ongoing, 
but not recruiting participants. 
 
1.4 Cell death and autophagy 
1.4.1 Apoptosis: 
Apoptotic cell death can be started in three ways: via the intrinsic (mitochondrial), the extrinsic 
(death receptor-mediated) and granzyme B pathways (Figure 5). In all of them activation of a 
protease is the first execution step (125). 
Intrinsic pathway: 
Sustained cellular stresses such as DNA damage, viral infection, transcriptional/translational 
inhibition, protein misfolding and growth-factor deprivation can initiate the intrinsic pathway 
(125, 126). Induction of Bcl-2 homology domain 3 (BH3)-only proteins such as BIM and p53 
upregulated modulator of apoptosis (PUMA) or inactivation of some BCL-2 family members 
like Bcl-2, Bcl-xL and Mcl-1, leads to oligomerization of Bcl-2-associated X (Bax) and Bcl-2 
homologous antagonist killer (Bak) on the mitochondrial membrane which in turn promotes 
cytochrome c release and mitochondrial fission (126, 127). Bax is mainly present as an inactive 
soluble monomeric protein in the cytosol of healthy cells while Bak is constitutively integrated 
in the mitochondrial outer membrane (126). These events are followed by formation of 
apoptosomes and activation of caspase-9 and then caspase-3 and caspase-7 (127). Activation 
of caspase-3 and caspase-7 mediates proteolysis of caspase substrates like catenin, Rho-
associated kinase 1 (Rock1), lamins, mammalian STE20-like kinase 1(MST-1) (128), and 
further inhibitor of caspase activated DNase (ICAD) and p75 which leads to cell detachment, 
nuclear fragmentation, membrane blebbing, chromatin condensation, DNA degradation, 
accumulation of  ROS and deactivation of high mobility group box 1 (HMGB1) (125).  
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The extrinsic pathway 
Binding of extrinsic death ligands of the tumor necrosis factor (TNF) family to their receptors, 
such as CD95, death receptor 5 (DR5) or TNF receptor 1 (TNFR1) recruits the proteins of 
receptor-associated death-inducing signaling complex (DISC) (125). DISC comprises of an 
adapter like FAS-associated death domain protein (FADD) or TNFR1-associated death domain 
protein (TRADD), and zymogen caspase-8. Subsequent to caspase-8 activation, via a proximity 
induced model, caspase-3 and caspase-7 are activated downstream, which in turn execute 
apoptosis in targeted cell. BH3 interacting-domain death agonist (BID), a pro-apoptotic 
protein, may also be cleaved and activated by active caspase-8 (129, 130). 
The granzyme B pathway 
Cytotoxic T lymphocytes release lytic granules that contain granzyme B and perforin. 
Granzyme B is internalized by the mannose 6-phosphate/insulin-like growth factor II receptor 
(131). Granzyme B internalization is also facilitated by perforin and initiates apoptosis by 
activation of caspase-8 and caspase-3 or cleavage of BID that triggers mitochondrial 
cytochrome c release and apoptosome formation (132). 
 
 
Figure 5. Apoptotic cell death. Reproduced with permission from Self-consumption: the interplay of 
autophagy and apoptosis. Guillermo Mariño, Mireia Niso-Santano, Eric H. Baehrecke & Guido Kroemer, Nature 
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1.4.2 Necroptosis 
Another regulated cell death which results in cellular leakage is necroptosis (133, 134). A DISC 
is formed following the binding of ligand to TNFR1. Lys63-deubiquitylating enzyme 
cylindromatosis (CYLD) removes ubiquitin from Receptor-interacting serine/threonine-
protein kinase 1 (RIP1) which leads to recruitment of RIP1, RIP3, FADD, TRADD and 
caspase-8. In this complex, caspase-8 inactivates RIP1 and RIP3 by proteolytic cleavage and 
promotes apoptosis. If caspase-8 is deleted, depleted or inhibited, this complex cannot proceed 
to apoptosis and instead, causes programmed necrosis or necroptosis. The role of FADD and 
TRADD is not clear in necroptosis. Necrostatin 1 and necrostatin 3 are small molecules that 
inhibit the kinase activity of RIP1, thereby inhibiting necroptosis (133, 134). 
1.4.3 Autophagy 
Autophagy is a highly conserved process from yeast to mammals in which portions of cytosol 
and aberrant organelles are sequestered by a double-membrane vesicles, termed the 
phagophore. The phagophore is elongated and closed, which is called autophagosome (Figure 
6) (135, 136). Autophagosomes are fused with lysosomes to breakdown the macromolecules 




Figure 6. Process of autophagy. Reproduced with permission from Self-eating and self-killing: crosstalk 
between autophagy and apoptosis, M. Chiara Maiuri, Einat Zalckvar, Adi Kimchi & Guido Kroemer.Nature 




The core machinery process of autophagy in mammalian cells can be divided into five steps 
(137): 
 
1. Initiation of autophagy: 
Unc-51 like autophagy activating kinase 1/2 (ULK1/2), FAK family kinase-interacting 
protein of 200 kDa (FIP200), autophagy-related gene13 (ATG13) and ATG101 form a stable 
complex in both nutrition-rich and starvation condition (138). In nutrition-rich conditions 
mTORC1 binds to the complex through direct interaction between raptor and ULK1/2 and 
phosphorylates both ULK1/2 and ATG13, thereby inhibiting ULK1/2 kinase activity. Upon 
starvation, mTORC1 is released from the complex leading to that the mTORC1-dependent 
phosphorylation sites (such as S638 and S758) in ULK1/2 rapidly become dephosphorylated 
by unknown phosphatases. Activation of ULK1/2 leads to its autophosphorylation and further 
phosphorylation of ATG13 and FIP200 that translocate the whole complex to the pre-
autophagosomal membrane (139). 
 
2. Vesicle nucleation: 
The Beclin 1–Vps34 complex includes several protein such as Beclin 1, Vps34, Vps15, 
Autophagy/Beclin 1 Regulator1 (AMBRA1), UV radiation resistance associated gene 
(UVRAG), Rubicon and ATG14L. The Beclin 1–Vps34 complex is recruited to the 
autophagosome formation site by the activated ULK1 complex via phosphorylation of 
AMBRA1 (140). The activated ULK1 complex, also phosphorylates Ser14 on Beclin 1 
enhancing the activity of the ATG14L containing Vps34 complex (141). Vps34 complex 
kinase activity produces PtdIns(3)P which binds to effector proteins like double FYVE-
domain-containing protein 1 (DFCP1) and WD-40 repeat-containing protein that interacts with 
PtdIns (WIPI) and recruits them to promote autophagosome formation (142). AKT inhibits 
autophagy by direct phosphorylation of Ser234 and Ser295 of Beclin 1(143). EGFR inhibits 
autophagy via phosphorylation of Tyr229, Tyr233, and possibly Tyr352 on Beclin 1 leading to 
decrease Beclin 1-associated VPS34 kinase activity (144). BCL2 or Bcl-xL can bind to the 
BH3 domain of Beclin 1 and inhibits autophagy (137). 
 
3. Retrieval 
ATG9 and vacuole membrane protein 1 (VMP1) are two transmembrane proteins which 
undergo recycling between the Golgi, endosomes and autophagosomes (137). Atg9 transfers 
membrane components which required for phagophore expansion. VMP1 might function as a 
transmembrane protein to recruit Beclin 1 (145, 146). 
 
4. Vesicle elongation 
The vesicle elongation process compromises of two ubiquitin-like conjugation systems. 
ATG7, an E1-like enzyme, is present in both pathways. ATG3 and ATG10 are E2-like 
enzymes (147). The first pathway includes ATG7, ATG10, ATG16 and ATG12 that is 
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covalently bound to ATG5 (147, 148). ATG16 is required for the translocation of this complex 
to isolation membranes (149). The second pathway includes ATG3 and ATG7 and the 
conversion of microtubule-associated protein 1A/1B-light chain 3-I (LC3-I) (the soluble form) 
to LC3-II (autophagic vesicle-associated form) by conjugation of phosphatidylethanolamine 
(PE) to LC3-I (150). Both the inner and outer membrane of the autophagosomes has LC3-II 
(151). LC3-II is used as a marker of autophagy. ATG4 is a protease that cleaves LC3 to form 
LC3-I (152). Ubiquitin-binding proteins are involved in the recognition of autophagy targets 
such as p62 which contains a carboxy-terminal ubiquitin-associated (UBA) domain, Phox and 
Bem1 domain (PB1) and an LC3-interacting region (LIR). p62 acts as an adapter between 
ubiquitinylated autophagy substrates (e.g. protein aggregates, organelles) and the autophagic 
machinery (153). The E3 ligase parkin and p62 have been implicated in autophagy of non-
functional mitochondria (154). p62 also plays an important role in autophagic degradation of 
soluble proteins (155). 
 
5. Fusion with lysosomes and degradation 
Soluble N-ethylmaleimide-sensitive fusion attachment protein receptors (SNAREs), 
including vacuolar morphology protein 7 (VAMP7), vacuolar morphology protein 8 
(VAMP8), and vesicles transport through interaction with t-SNARE homolog 1B (VTI1B), are 
involved in docking and fusion of the autophagosomes to lysosomes (156). 
 
1.5 Multiple Myeloma 
Multiple myeloma (MM) accounts to 1% of all cancers and is the second most common 
hematological malignancy (157). Multiple myeloma is characterized by accumulation of 
monoclonal, terminally differentiated B cells (plasma cells), in the bone marrow and the 
production of either complete immunoglobulins (most frequently IgG or IgA) or only 
immunoglobulin light chains (either kappa or lambda but not both of them) (158). Multiple 
myeloma is diagnosed based on the presence of such clonal plasma cells in the bone marrow, 
the monoclonal immunoglobulin chains in serum (M protein), and clinical indications of end 
organ damage such as hypercalcemia, renal failure, anemia and lytic bone lesions (CRAB) 
(159). 
 
1.5.1 Risk factors for multiple myeloma  
The most common risk factors associated with multiple myeloma are (160): 
1. Age: incidence rate increase after the age of 40 and most diagnosed patients are more 
than 65 years old. Only 2% of patients are diagnosed when they are younger than 40 
years old. 
2. Ethnicity: myeloma has a higher incidence in African American. 
3. Gender: Myeloma risk is elevated in men. 
4. Obesity: Obese persons have a higher risk to develop myeloma. 
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5. Family history: People with a positive family history of lymphatohematopoietic 
cancers have a higher risk of myeloma. 
6. Radiation: Exposure to radiation increases the risk of myeloma. 
 
1.5.2 Genetic Abnormalities 
Specific genetic changes of multiple myeloma do not play a role in diagnosis but they can be 
used to assign patients to different risk groups which determine choice of treatment and 
prognosis (161). Multiple myeloma is classified into two groups: hyperdiploid and non-
hyperdiploid, which have almost the same number of patients. Hyperdiploid patients usually 
have better survival compared to non-hyperdiploid patients. Hyperdiploid multiple myeloma 
has extra copies of chromosomes while non-hyperdiploid is characterized by translocations of 
the IgH locus (14q32) with other chromosomal parts like 11q13, 4p16, 16q23. The 
t(11;14)(q13;q32) translocation, fusing IgH with CCND1 gene is the most frequent 
translocation which is associated with low levels of serum monoclonal proteins, low plasma 
cell proliferation and good prognosis. The t(4;14)(q16;q32) and the t(14;16)(q32;q23), fusing 
IgH with CCND1 gene , translocations are associated with poor prognosis with the former 
having  aggressive clinical features. Other abnormalities like deletion of 17p, detected in 10% 
of newly diagnosed cases, and chromosomes 13 deletion, found in 50% of cases at the time of 
diagnosis, are also common in multiple myeloma. 
 
1.5.3 Pathogenesis 
Myeloma rise out of a specific population of plasma cells (PCs) in the bone marrow which is 
termed myeloma cancer stem cells (162). The myeloma cancer stem cells are not well defined 
but there is a report showing clonogenic myeloma cells expressing the B cell surface antigens 
(CD19, CD20, CD22 and CD45) but not CD138. These cells have capacity to later become 
mature CD138+ plasma cells which produce circulating M protein and myeloma colonies 
(162). 
Genes for variable regions of the heavy and light chains of antibodies in B-cell progenitors 
rearrange to start the development of B cells. This process called V(D)J recombination (163). 
PCs proliferate and differentiate at the pre-germinal-center after primary exposure of mature B 
cells to antigen. These PCs are short lived and usually secrete IgM. Somatic hypermutation of 
IgH and IgL V(D)J sequences occurs in antigen-activated lymphoblasts that enter a germinal 
center. Some cells, which express high levels of antigen receptor, are selected and generate 
memory B cells or post-germinal-center plasma cells. Finally IgH switch recombination occurs 
in more differentiated cells, and these non-proliferating cells stay in the bone marrow. 
Terminally differentiated normal plasma cells highly express the CD138 antigen (164-168). 
Multiple myeloma progression start from germinal center B cells and is developed further to 
monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple 
myeloma (SMM), intramedullary myeloma, extramedullary myeloma and finally independent 
myeloma cell line (Figure 7). Almost all cases of multiple myeloma proceed from the 
premalignant state MGUS (169). It is estimated that the prevalence of MGUS is 3.2% in people 
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older than 50 years and the prevalence is affected by age and sex. The risk of progression of 
MGUS to multiple myeloma is approximately 1% per year (170). MGUS is characterized by 
the clonal expansion of plasma cells in the bone marrow, less than 10%, and monoclonal 
protein in serum (serum M protein),  less than 3 g/dL, and without any clinical manifestations 
or other laboratory abnormalities related to monoclonal gammopathy (171). Hyperdiploid and 
non-hyperdiploid abnormalities which are seen in myeloma are also detected in MGUS. 
Patients with MGUS must be examined for detection of early signs of disease progression. 
Smoldering myeloma is characterized by the presence of plasma cells in the bone marrow equal 
or more than 10%, monoclonal protein in serum (serum M protein)  equal or more than 3 g/dL 
and without any clinical manifestations or other laboratory abnormalities related to monoclonal 
gammopathy (171). The risk of progression of SMM to MM is 10% per year for the first 5 
years, then decreases to 3% per year for the next 5 years (172). 
Kuehl and Bergsagel divide pathogenesis of MGUS and myeloma into three phases: in the 
early phase primary IgH translocation, hyperdiploidy, and chromosomes 13 deletion take place 
which dysregulate the cyclin D1 gene (173, 174). The second phase is associated with v-
myc avian myelocytomatosis viral oncogene homolog (MYC) overexpression, sometimes 
Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation and chromosomes 13 deletion. 
The third phase is associated with increased proliferation and genomic instability and the cells 
are less dependent on the bone marrow microenvironment. Activation of the NFκB pathway 
and inactivation of TP53, P18 and RB1 have also been reported (173, 174). 
 
 
Figure 7. Multiple myeloma development. Reproduced with permission from Multiple myeloma: 
evolving genetic events and host interactions, W. Michael Kuehl & P. Leif Bergsagel. Nature Reviews Cancer 2, 
175-187 (March 2002). 
 
 40 
1.5.4 Signaling cascades involved in multiple myeloma pathogenesis 
The four main signaling cascades that have been shown to be activated in multiple myeloma 
are PI3K/AKT/mTOR, JAK/STAT3, Ras/Raf/MEK/ERK and NFκB (175). 
These signaling pathways were generally described before in the thesis and here I will describe 
their specific special role in myeloma pathogenesis. 
 The PI3K/AKT/mTOR signaling pathway 
PI3/AKT/mTOR activation leads not only to increased survival, proliferation and migration 
but also to the overexpression of anti-apoptotic proteins in myeloma cells (175). Several growth 
factors activate this signaling pathway. IGF-1 and insulin are survival and proliferation 
inducers in most primary myeloma cells as well as cell lines. The IGF-1R is expressed 
aberrantly by myeloma cells but not in normal plasma cells (176, 177). IGF-1 is secreted by 
octeoclasts in the bone marrow and its level is high in bone marrow of multiple myeloma 
patients (176, 178). CD138 is a hallmark of myeloma cells CD138 mediates adhesion of 
myeloma cells to collagen and myeloma cell-cell adhesion which is very important in myeloma 
growth and development. Many growth factors such as HGF , VEGF and FGF2 interact with 
heparan sulfate of CD138  (179).  
 
 The JAK/STAT3 signaling pathway 
One of the main growth factors for myeloma is IL-6 (180) which can directly activate both the 
JAK/STAT3 and Ras/Raf/MEK/ERK signaling pathways by binding to its receptor, gp130 
(181). The receptor gp130 phosphorylates the tyrosine (Tyr99) on JAK which leads to the 
recruitment and phosphorylation of mainly Tyr705 in STAT3 and Tyr701 in STAT1. 
Subsequently active STAT dimers are formed and translocated to the nucleus initiating the 
transcription of genes that are promote expression of anti-apoptotic protein like Mcl-1 and Bcl-
xL in the myeloma cells (181-184). Phosphorylated JAK also phosphorylates Shc which leads 
to the activation of the Ras/Raf/MEK/ERK pathway which induces proliferation of myeloma 
cells (183).  
 
 The Ras/Raf/MEK/ERK signaling pathway 
This pathway is induced by the activation of IGF-1R and IL-6R as described above. Activation 
of this signaling pathway leads to increased proliferation of myeloma cells (175). 
 
 The NFκB signaling pathway 
Tumor necrosis factor alpha (TNF-α) family members like BAFF and APRIL are very 
important in multiple myeloma pathogenesis (185). These molecules bind to the TNF family 
receptors including B-cell maturation antigen (BCMA) and transmembrane activator and 
calcium modulator and cyclophilin ligand interactor (TACI) and activate the NFκB, PI3K/AKT 
and Ras/Raf/MEK/ERK signaling pathway which is important in survival and proliferation of 
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normal and malignant B cells. Activation of these signaling cascades also up-regulate the Mcl-
1 and Bcl-2 anti-apoptotic protein levels in myeloma cells (185-187).  
 
1.5.5 Role of the microenvironment in myeloma 
Apart from the end stage of multiple myeloma, myeloma cells cannot grow outside of the bone 
marrow, indicating the importance of the bone marrow microenvironment for the myeloma cell 
survival and proliferation (Figure 8) (188). The direct interaction between bone marrow cells 
and multiple myeloma cells leads to growth, survival, migration of myeloma cells and 
osteolysis (188-190) and neovascularization by secreting growth factors, cytokines, and 
extracellular vesicles (191, 192). The major players in myeloma pathogenesis in the bone 
marrow are bone marrow stromal cells (BMSCs), osteoblast, osteoclasts and extracellular 
matrix (ECM).    
Attachment of multiple myeloma cells to extracellular matrix (ECM) and BMSC mediates the 
homing of myeloma cells in bone marrow. VLA-4 on myeloma cells binds to the vascular cell 
adhesion molecule 1(VCAM-1) on BMSCs which activates the NFκB pathway and increases 
IL-6 secretion from BMSC (193). Subsequently, IL-6 increases the secretion of VEGF and 
TNFα from myeloma cells which in turn upregulate IL-6 secretion from BMSC via a paracrine 
loop (194, 195).  Recently Wang and colleagues showed that BMSC-derived exosomes 
increase the multiple myeloma cell growth and induce drug resistance to bortezomib by 
influencing the activation of several pathways such as JNK, p38, p53, and AKT (191). Other 
soluble factors like VEGF, IGF1, stromal cell-derived factor α (SDF1α), B-cell activating 
factor (BAFF), a proliferation-inducing ligand (APRIL) and HGF are also secreted by BMSC 
and play an important role in myeloma pathogenesis (175). Bone marrow microvessel density 
(MVD) is consistently increased in active myeloma. This is primarily due to the secretion of 
angiogenesis promoting factors like VEGF and metalloproteinases from myeloma cells (175, 
196). Adhesion of myeloma cells to ECM through binding of β1-integrin to fibronectin has an 
important role in the multi-drug resistance phenotype. It can be mediated via the nuclear 
accumulation of Spy1 and p27Kip1 (197, 198). 
Lytic bone lesion and bone resorption which is seen in myeloma is caused by two mechanisms: 
first the binding of the myeloma cells to BMSCs causing the increased production of receptor 
activator of NFκB ligand (RANKL). RANKL binds to the receptor activator of NFκB (RANK) 
on the osteoclast precursors and induces their differentiation to osteoclasts. On one hand 
RANK signals via NFκB and JNKs pathways increase osteoclastic bone resorption and 
osteoclast survival. On the other hand, it decreases the secretion of osteoprotegerin (OPG) from 
BMSCs. OPG is a soluble decoy receptor for RANKL (199). The second mechanism for bone 
resorption is mediated by the secretion of macrophage inflammatory protein-1α (MIP-1α) from 
myeloma cells. MIP1α induces osteoclast formation (200). Decreased activity of osteoblasts 






Figure 8. Interaction of multiple myeloma cells in their bone marrow microenvironment. 
Modified with permission from Understanding multiple myeloma pathogenesis in the bone marrow to identify 
new therapeutic targets. Teru Hideshima, Constantine Mitsiades, Giovanni Tonon, Paul G. Richardson & Kenneth 
C. Anderson, Nature Reviews Cancer 7, 585-598 (August 2007) 
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1.5.6 Clinical and laboratory finding: 
The clinical manifestations of myeloma are hypercalcemia (≥11 mg/dL), renal failure due to 
nephropathy or hypercalcemia and elevated serum creatinine (in 50% of patients at the time of 
diagnosis), pallor, weakness and fatigue because of anemia (in 70% of patients at the time of 
diagnosis), bone pain (in 60% of patients at the time of diagnosis) usually in the back and the 
ribs (202). These four manifestations (CRAB) are major difference between MGUS and 
multiple myeloma. Other symptoms and signs are radiculopathy, infection and organ 
infiltration. Laboratory findings of multiple myeloma are normocytic normochromic anemia, 
rouleaux formation in peripheral blood smear, single narrow peak in the serum protein 
electrophoresis, monoclonal protein in the serum while two-thirds of cases are kappa light chain 
and one-thirds are lambda. Usually more than 10% of the bone marrow cells are monoclonal 
plasma cells and the cytoplasm of these cells contains only kappa or lambda chain. Myeloma 
cells are positive for CD38 and CD138 and two-thirds of these express CD56. Lytic lesions, 
osteoporosis and pathologic fracture are seen by radiography. The most common bone 
involvements are vertebra, skull and thoracic cage. 
1.5.7 Treatment 
Multiple myeloma is considered as an incurable but manageable disease with a median survival 
of 3-4 years (203). The treatment of multiple myeloma involves seven steps: 
1. Diagnosis and determination of need for therapy 
It is necessary to show that a monoclonal plasma cell process is ongoing and that it is 
in an active phase which needs treatment. 
2. Risk stratification  
Three risk factors must be considered in the treatment of myeloma: age, renal function 
and type of genetic abnormalities. 
3. Induction therapy 
Based on the eligibility of patients for autologous stem cell transplantation, initial therapy 
includes lenalidomide and dexamethasone (RD), bortezomib and dexamethasone (VD), 
cyclophosphamide, bortezomib and dexamethasone (CyBroD or VCD), bortezomib, 
lenalidomide and dexamethasone (VRD), melphalan, prednisolone and thalidomide 
(MPT), melphalan, prednisolone and lenalidomide (MPR) and finally melphalan, 
prednisolone and bortezomib (VMP). 
4. Consolidation therapy 
5. Maintenance therapy 
6. Monitoring for relapse 
7. Supportive care, including biphosphonates used for reducing the bone problem (202).  
 
1.5.8 Mouse models of multiple myeloma 
The role of animal models has a significant impact on our understanding of mechanisms of 
diseases and the discovery of new treatments. There are several different mouse models of 
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multiple myeloma like LAG λ-1 (204) model or MOPC315.BM (205). Here I describe some 
common models. 
 The 5T series 
Jiri Radl observed in the 1970s that C57BL/KaLwRij mice sometimes developed myeloma 
when they grow old. He isolated and injected these myeloma cells into young mice and found 
that threy infiltrate bone marrow and injected mice developed multiple myeloma (206). He 
repeated this process several times and established a new mouse models of myeloma which is 
known as the 5TMM syngeneic mouse model. Localization of myeloma cells and increased 
angiogenesis in bone marrow, positive correlation between serum paraprotein and myeloma 
stage and osteolytic bone lesions are some of the main characteristics of this models and 
resemble closely the human disease. The 5T2MM and 5T33MM are two well characterized 
models with the latter being more aggressive. Signs of myeloma are seen after 12 weeks post-
injection and are found in the in the bone marrow and spleen demonstrating that these myeloma 
cells are dependent on the bone marrow stromal cells for growth and survival (207). This model 
has been used to study myeloma cell homing and efficiency of new treatments (208). 
 
 SCID models 
There are several experimental systems of immortalized or primary human cells injected 
subcutaneously into severe combined immunodeficiency (SCID) mice (209-212). Urashima 
and colleagues implanted human fetal bone grafts in SCID mice and then injected human 
myeloma cells directly into the graft. In this model, human bone grafts can provide an 
appropriate niche for human myeloma cells which need interaction with the human bone 
microenvironment (213). Primary human myeloma cells are solely dependent on the engrafted 
human bone and there are no myeloma cells found in any of the mouse organs. The SCID-hu 
model is suitable to investigate the natural history of multiple myeloma regarding bone 
resorption or angiogenesis and efficacy of new treatment (214). 
 
 Transgenic mouse models 
It was observed that mice with several genetic abnormalities can develop a myeloma-like 
disease. Chesi and colleagues showed that misdirecting the activity of activation-induced 
deaminase (AID) to a conditional MYC transgene can cause multiple myeloma Vk*MYC mice 
(215). Carrasco et al. also showed that transgenic mice with Eμ-directed expression of the XBP-
1 spliced isoform (XBP-1s) displays an MGUS and myeloma phenotype (216). The Jackson 
Laboratory also created several transgenic mice such as B6.129S1-Irf4tm1Rdf/J, B6; 129S6-
Lig4tm1Fwa/Kvm, C3.B6-Tg(Fabp1-Ccnd1)4Rdb/J, C57BL/6-Tg(Fabp1-Ccnd1)4Rdb/J and 




  45 
1.6 Prostate cancer 
According of Globocan report, prostate cancer comprises 15% of all cancers diagnosed in men 
worldwide (218). It is the second most common cancer and the fifth leading cause of cancer-
related deaths in men. In 2012 around 1.1 million men (2 men every minute) were diagnosed 
with prostate cancer worldwide. Ratio of highest to lowest incidence in the world is more than 
25-fold. The highest rates (approximately 70% of cases) occur in Australia, New Zealand, 
Northern America, and in Western and Northern Europe and the lowest rate are found in 
Eastern- and South-Central Asia. 
The most common form of prostate cancer is moderately differentiated adenocarcinoma which 
in 70 to 80% of cases and arises in the peripheral zone of prostate gland (13).  
 
1.6.1 Risk factors for prostate cancer 
1. Age: Based on Globocan report, prostate cancer is never seen in men younger than 15 
years old which shows the critical role of androgen hormone in prostate cancer 
development (218). The incidence of prostate cancer increases dramatically from 60 
years of age with the highest rate in men over 75 years of age. 
 
2. Family history: It was reported that men who have a first-degree male relative (i.e. 
father, brother, son) with a history of prostate cancer have a 2- to 3-fold increased risk 
of prostate cancer (219). There are some reports that suggest associations between 
genetic variants in genes such as Hereditary Prostate Cancer 1 (HPC-1), breast cancer 
1/2 (BRCA1/2), homeobox B13 (HOXB13) (which are more common in Scandinavian 
men), Nijmegen breakage syndrome1 (NBS1), checkpoint kinase 2 (CHEK2) and 
PALB2 and prostate cancer but it needs further investigations (220). 
 
3. Physical activity: Physical activity may decrease the risk of prostate cancer by 
decreasing levels of total and free testosterone, reducing obesity, and enhancing 
immune function (219). 
 
4. Diet: There are some evidences that diet and lifestyle plays a role in prostate cancer 
pathogenesis (221). Red meat, well cooked and processed meat increase the risk of 
developing prostate cancer by producing heterocyclic amines and heme compounds. 
Excessive consumption of milk and dairy products is also consider as risk factor of 
prostate cancer due to increase fat intake and blood levels of IGF-1 and a decrease in 
circulating 1,25 dihydroxyvitamin D3. 
 
5. Smoking: Because smoking is a known source of carcinogens, it is suggested that 
smoking is a risk factor for prostate cancer (222). A meta-analysis report enrolling 
21,579 prostate cancer cases showed that current smokers had higher risk of fatal 




6. Alcohol: Most studies cannot show any association between alcohol consumption and 
prostate cancer, but increased alcohol intake is associated with the risk of high-grade 
prostate cancer in patients which use dutasteride, a 5α-reductase inhibitor (223). 
 
7. Sexual activity: Because prostate cancer tumorigenesis is associated with infection and 
inflammation in the prostate gland, it is possible that sexual activity increases the risk 
of prostate cancer (224). There are some reports indicating that starting sexual 
intercourse at an early age and higher number of sexual partners increases the risk of 
prostate cancer. It is also shown that higher frequency of ejaculation decreases the risk 
of prostate cancer but association of sexual activity and prostate cancer needs further 
investigation. 
 
1.6.2 Pathogenesis of prostate cancer 
A multi-step progression pathway was suggested for prostate cancer development (Figure 9) 
(225). It is initiated from normal prostate tissue damage by different mutations like hereditary 
prostate cancer 1 (HPC1) gene mutation, oxidative damage, dietary and environmental factors, 
infection and inflammation in prostate tissue which leads to prostatic inflammatory atrophy 
(PIA). Prostatic intraepithelial neoplasia (PIN) is characterized by loss of heterozygosity 
(LOH) involving chromosome 8p21 and the transcription factor NKX3.1 as a putative tumor 
suppressor gene in prostate cancer, overexpression of MYC, up regulation of glutathione S-
transferase π (GSTP1) in response to increased oxidative stress, increase expression of α -
Methylacyl-CoA racemase (AMACR) and decrease in telomere length. Progression of PIN 
towards prostate cancer is associated with loss of 10q (phosphatase and tensin homolog 
(PTEN)) and 13q (RB), abnormal methylation of the Ras association (RalGDS/AF-6) domain 
family member 1 (RASSF1A), and a reduced level of p27 that may be secondary to PTEN loss, 
increased activity of telomerase and prostate stem cell antigen (PSCA). Loss of 17p (p53) and 
decreased activity of E-cadherin is further associated with metastasis in prostate cancer (225-
227). 
1.6.3 Role of NRTK in prostate cancer: 
 Src family:The Src family consists of nine members which play an important role in 
pathogenesis and metastasis of prostate cancer (228). Src makes a complex with Fak and 
Etk which interact and enhance the effect of each other. These complexes are involved in 
the activation of the androgen receptor (AR), EGFR, IGFR and VEGF mediated signaling 
in prostate cancer. Src activity is enhanced in hormone refractory prostate cancer and in a 
closed loop process, Src can activate AR as well as being a downstream target of the AR. 
Src is involved in growth, migration and metastasis of prostate cancer cells (229). FYN can 
regulate cyclooxygenase 2 (COX2) by direct phosphorylation. COX2 in turn is involved in 
the initiation and progression of prostate cancer (230).  
 TEC family:This family comprises of four members. Etk/Bmx expression is increased in 
prostate cancer and its overexpression leads to PIN in mouse model (231, 232). The levels 
of Etk/Bmx are also increased in castration-resistant prostate cancer (CRPC) (231, 232). 
Etk is further involved in IL6-dependent induction of neuroendocrine differentiation in 
prostate cancer cell lines (233). 
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Figure 9: Prostate cancer development. Reproduced with permission from Unconventional therapy for 
prostate cancer: good, bad or questionable? Peter S. Nelson & Bruce Montgomery, Nature Reviews Cancer 3, 845-
858 (November 2003). 
 
 FAK family:FAK expression is elevated during prostate cancer pathogenesis (234). 
Integrins, neuropeptides, chemokines and growth factors stimulate FAK which leads to 
migration, growth, cell polarity, adhesion and metastasis through Src, PI3K, RhoGTPase, 
and p130Cas pathways. FAK can increase VEGF transcription through ERK1/2 and affects 
angiogenesis and apoptosis (28). 
 JAK family: Binding of IL-6 to its receptor can activate JAK1 and STAT3 in prostate 
cancer cells, which is known to be important in progression of hormone sensitive to the 
hormone refractory situation (235). The concentrations of IL-6 in the serum of patients with 
hormone sensitive prostate cancer is less than in patients with hormone refractory prostate 
cancer. The IL-6 receptor/JAK/STAT3 cascade also increase the proliferation rate of 
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prostate cancer cell lines and AR-negative cells such as DU145 and PC3 having higher 
level of activated STAT3 than AR-positive cells like LNCaP. 
 
1.6.4 Role of RTK in prostate cancer 
 EGFR:The human epidermal growth factor receptor (HER) family comprises of four type 
1 transmembrane receptors: EGFR, HER2 (ErbB2), HER3 (ErbB3) and HER4 (ErbB4) 
(236). They undergo homodimerization or heterodimerization with another family member 
upon binding of the ligand and activate downstream signaling pathways like the ERK1/2 
and the phosphatidylinositol 3-kinase (PI3K)/AKT pathways. Overexpression of EGFR, 
HER2 and HER3 are associated with progression from localized to metastatic prostate 
cancer and to the androgen-independent state (236-238). 
 FGFR:The FGFR family consists of four receptors. They can activate the Raf/Ras/ERK, 
PI3K/AKT, PLCγ and STAT pathways. Normal epithelial cells of prostate express multiple 
FGF receptors. While there is enough evidence to support the role of FGFR-1, FGFR-3 and 
FGFR-4 in prostate cancer initiation and progression, the role of FGFR-2 is not clear. 
Twenty two FGFs were identified so far in the human proteome, some of which have an 
autocrine and/or a paracrine role in prostate cancer (239, 240). 
 HGFR:Stromal cells produce HGF in normal tissues and HGF/c-Met signaling usually 
occurs through paracrine mechanisms (241). c-Met  can activate downstream signaling 
molecules like the Src kinase, PI3K/AKT/mTOR and Ras/Raf/MEK/ERK which promote 
cellular proliferation, survival and motility, resistance to apoptosis and metastasis. A c-
Met/HGF paracrine loop is responsible for increased c-Met signaling in prostate cancer. 
Half of primary prostate tumors and almost all bone metastases have high expression of c-
Met. 
 IGF-1R:Different mechanisms are involved in the regulation of IGF-1R transcripts in 
prostate cancer cells such as defective BRCA1 and Kruppel-like factor 6 (KLF6), 
epigenetic changes of  paired-like homeodomain transcription factor 2 (PITX2) gene which 
is an upstream regulator of IGF-1R gene expression and IGF-1R translocating to the 
nucleus (242, 243). BRCA1 regulates the IGF-IR expression in an AR-dependent manner 
in prostate cancer. The IFG-1R activates PI3K/AKT and Raf/Ras/MEK/ERK. IFG-1R can 
also facilitate the metastatic potential of prostate cancer cells by transactivation of IGF-IR 
with IL-6 and induction of epithelial to mesenchymal transition (244). Increased level of 
IGF-1R, IGH-1 and IGF-2 has been reported in advanced prostate cancer (242, 243). 
 PDGFR:The PDGFR is detected in 88% of prostate cancer primary tumors and 80% of the 
metastases. It has been reported that PDGF-BB can upregulate Mcl-1 through activation of 
β-catenin and hypoxia-inducible factor (HIF)-1α in metastatic prostate cancer (245, 246). 
 
1.6.5 Signaling cascades activated by RTKs and NRTKs in prostate cancer 
PI3K/AKT/mTOR is one of the major survival pathway which is activated in prostate cancer. 
Loss-of-function mutation or deletion of PTEN leads to an increase in AKT phosphorylation 
levels in prostate cancer (247). This downstream pathway is activated both with NTRK and 
RTK. The other important signaling pathway is Ras/Raf/ERK which causes cell growth, 
malignant transformation and drug resistance (248). 
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1.6.6 The role of the microenvironment in prostate cancer 
The tumor microenvironment consist of both a cellular component including malignant cells, 
fibroblasts, inflammatory cells, adipocyte, vessel-related cells, mesenchymal stem cells and a 
non-cellular component including factors such as collagen, elastin and glycoproteins forming 
the extracellular matrix (ECM) (Figure 10). Stromal support is necessary for prostate tumor 
formation. Tumor stroma becomes reactive during progression of prostate cancer from PIN to 
metastatic disease and it is also important in development of androgen resistance (249).  
 Involvement of the extracellular matrix (ECM) 
ECM comprises of collagen, elastin, fibronectin, laminin, and polysaccharide. ECM proteins 
interact with integrins which regulate the attachment of epithelial cells to the basement 
membrane. Integrins which are expressed on malignant cells and activated endothelial cells 
interact with ECM and recruit FAK, activate Src and PI3K and finally activate the MAPK 
signaling pathway (249). 
 Cellular components  
Inflammation is known one of the hallmark of cancer and the role of inflammation and 
inflammatory cells in prostate cancer is well-described (250). The tumor vasculature differs 
from normal vessel in many aspects like aberrant vascular structure, different endothelial-cell–
pericyte interactions, increased permeability and delayed maturation (251). It has been recently 
shown that bone marrow mesenchymal stem cells which infiltrate prostate tissue cause an 
increase in the number of prostate cancer stem cells and promotes the metastatic ability (252). 
Cancer associated fibroblasts (CAFs) characterized by expression of smooth-muscle actin 
(SMA), fibroblast-activated protein (FAP), fibroblast-specific protein-1 (FSP1/S100A4), 
neuron-glial antigen-2 (NG2) and the PDGF b receptor. Inactive resident fibroblast or 
fibroblast precursors are thought to be the cells of origin of CAF (253).  
 Molecular pathways in stromal-epithelial crosstalk 
Androgen signaling: Stromal cells can convert testosterone to the more potent androgen DHT 
or they can produce it locally from cholesterol or by conversion of adrenal androgens, by 
CYP17 which leads to the activation of the MAPK signaling pathway (249). AR signaling is 
also involved in the osteoblastic metastatic lesions. Osteoblasts, osteoclasts and bone marrow 
stromal cells express AR and they can respond to androgens and increase the growth of prostate 
cancer cells via increased local production of androgens and androgen‑independent crosstalk 
of AR with growth factor pathways (249, 254, 255).  
 
FGF signaling: FGFs and their receptors control the development of the prostate gland during 
embryogenesis and maintain normal tissue homeostasis in the adulthood (239). An FGF 
signaling crosstalk between stromal and epithelial prostate tissue plays a role in increasing 
cellular proliferation, motility and invasiveness, resistance to apoptosis, treatment and 




Figure 10. Interaction of prostate cancer cells in their bone marrow microenvironment. Modified 
with permission from Therapeutic targeting of the prostate cancer microenvironment Maria Karlou, Vassiliki 
Tzelepi & Eleni Efstathiou. Nature Reviews Urology 7, 494-509, September 2010) 
 
Src signaling: Src family kinases (SFKs) are essential for the interaction between malignant 
cells and tumor-associated bone stromal cells. Varkaris et al. have shown that these kinases 
promote bone remodeling during metastasis (257). Activation of Src leads to an increase in the 
secretion of VEGF from tumor cells, which leads to not only increased proliferation in tumor 
associated endothelial cells in a paracrine manner but also promotes tumorigenesis in an 
autocrine manner. 
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1.6.7 Clinical and laboratory findings 
Most of the patients are asymptomatic at the early-stage prostate cancer (258). Locally 
advanced or metastatic cases show symptoms like obstructive or irritative voiding and bone 
pain. In the presence of metastasis to the vertebral column, symptoms of back pain as well as 
of cord compression such as paresthesias and weakness of the lower extremities and urinary or 
fecal incontinence may be seen. It is possible to detect irregular hard nodules on digital rectal 
examination (DRE) if prostate cancer arise in the peripheral zone (258). PSA levels above 4.0 
ng/mL (4 µg/L) is also associated with higher chance of prostate cancer. Prostate-specific 
antigen (PSA) can increase in benign prostate hypertrophy (BPH), urinary tract infections, and 
prostatitis. On the other hand, PSA level can be lower than 4.0 ng/mL (4 µg/L) in 15% of 
prostate cancer patients (259). Since PSA has a limited positive predictive value, finding new 
prognostic and diagnostic biomarkers in prostate cancer is necessary. Other emerging 
biomarkers are PSA velocity and isoforms, human kallikreins, hypermethylation of certain 
cytosine guanine (CpG) dinucleotide islands, presence of the product of the TMPRSS2–ERG 
fusion gene, RNA biomarkers like PCA3 and Alpha-methylacyl CoA racemase (AMACR) and 
prostate-specific membrane antigen (PSMA) (260). 
 
1.6.8 Treatment 
 Low risk prostate cancer:  
By definition, low-risk prostate cancer is characterized by a Gleason Score of 6 or less and a 
PSA value less than 10 ng/ml (261, 262). About 50% of cases found by prostate cancer 
screening is diagnosed as low-risk. However, about one third of men diagnosed with low-risk 
disease have a high-grade cancer which could not be detected by the needle biopsy. A small 
proportion of low-grade cancers have molecular alterations which allow them to rapidly 
progress to aggressive disease. Low-risk prostate cancer should be managed by active 
surveillance with reservation of radical treatment for cases with higher-risk disease or possibly 
in younger patients. Active surveillance involves serial PSA assessments and biopsies from 
zones which are usually under-evaluated. If treatment is necessary, focal therapy or 
prostatectomy and radiotherapy are possible therapeutic options. 
 High risk prostate cancer:  
There are no common definitions for high-risk prostate cancer (263). American Urological 
Association defines it by a preoperative PSA greater than 20 ng/ml, and/or a preoperative 
Gleason score between 8 and10, and/or clinical stage ≥ T2c, while the European Association 
of Urology defines high-risk prostate cancer with the same condition but clinical stage ≥T3a.  
The purpose of treatment is a local control of cancer and the prevention of metastasis. It is well 
known that combination of androgen-deprivation therapy (ADT) and external-beam 
radiotherapy (EBRT) is better than either of these approaches alone. The treatment of clinically 
localized disease is initiated with neo-adjuvant therapy and then adjuvant therapy after 
surgery/radiotherapy. Another option for patients with high-risk prostate cancer is radical 
prostatectomy. Three to six months after prostatectomy, it is possible to start adjuvant 
radiotherapy in men with a high risk of local recurrence of cancer when the PSA value is 
 52 
undetectable (<0.2 ng/ml) and based on pathological features from the prostatectomy sample. 
In patients with a rising or detectable PSA after radical prostatectomy, salvage EBRT may be 
administered. Pre-chemotherapy with Sipuleucel-T (the first therapeutic cellular 
immunotherapy), Abiraterone (a 17 α-hydroxylase/C17,20 lyase (CYP17A1) inhibitor) or 
Radium-223 is followed by Docetaxel (a microtubule inhibitor) as first line chemotherapy 
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 2. Aims of the studies 
Derailment of tyrosine kinase signaling is known to be the driving force in different types of 
cancers. Small molecules are a new category of receptor tyrosine kinase inhibitors that are 
increasingly used in a personalized cancer therapy setting. The main aim of this thesis is to 
evaluate the anti-cancer effects of the multi TKI sorafenib. To achieve this purpose we worked 























3. Results and discussion 
Paper I: Sorafenib has potent antitumor activity against multiple myeloma in vitro, ex 
vivo, and in vivo in the 5T33MM mouse model 
Multiple myeloma is a neoplastic B-cell disorder characterized by the activation of multiple of 
tyrosine kinase signaling cascades that induce 3 main downstream pathways, the 
Ras/Raf/MEK/ERK1/2, PI3K/AKT, and the JAK/STAT3. Targeting of multiple activated 
tyrosine kinase signaling cascades with chemical inhibitors maybe a promising therapeutic 
strategy against multiple myeloma. 
In this study, we treated a panel of human myeloma cell lines comprising of U-266, LP1, OPM-
2, NCI-H929, RPMI-8226, and Karpas 620 with different concentration of sorafenib. We found 
that apart from one cell line, U-266 which is relatively resistant to Sorafenib (50% cell death 
after 72 hours of treatment with 10 µM Sorafenib), the rest of the cell lines are sensitive within 
24 hours of treatment with 10 µM sorafenib. This sorafenib concentration is a clinically 
relevant dose. We also showed that sorafenib induces apoptotic cell death characterized by 
mitochondrial depolarization, cytochrome c release, Bak and caspase-3 activation, and nuclear 
condensation/fragmentation. Our findings are in agreement with other sorafenib-myeloma 
studies (109-111).  
We further investigated apoptotic cell death and found that caspase-3 and caspase-7 were 
activated even after 8 hours treatment. The pan-caspase inhibitor z-VAD-fmk could inhibit cell 
death in U-266 and RPMI-8226 but not in the rest of cell lines. That indicates that sorafenib 
can induce both caspase-dependent and caspase-independent cell death in myeloma cell lines. 
We also reported that the apoptosis-inducing factor (AIF) is released from mitochondria into 
the cytoplasm in cell lines which undergo caspase-independent cell death, possibly providing 
an explanation on the mechanism of cell death in these cell lines.  
Since autophagy is a known cytoprotective mechanism we investigated whether multiple 
myeloma cells undergo autophagy in response to sorafenib. Sorafenib induced autophagy in 
some human myeloma cell lines, primary human myeloma cells and mouse myeloma cells. It 
is not clear whether sorafenib induced autophagy because of damaged mitochondria or due to 
the inhibition of tyrosine kinases. It is well established that damaged mitochondria are cleared 
by autophagy. Furthermore it is known that some tyrosine kinase inhibitors can induce 
autophagy primarily by shutting down the Src/PI3K/AKT/mTOR signaling cascade. 
Importantly, Co-treatment with sorafenib and 3-Methyladenine (3MA) which inhibits 
autophagy in early phase and chloroquine which inhibit autophagy in late stage, enhanced the 
cytotoxic efficacy of sorafenib.  
To elucidate the importance of signaling pathways involved in sorafenib-induced cell death, 
we examined the PI3K/AKT and Raf/Ras/MEK/ERK pathways. In OPM-2 cells, which are 
PTEN-null, the constitutively active AKT is partially inhibited by sorafenib. In the rest of the 
cell lines phospho-AKT level were rather increased or did not change. Apart from the LP-1 cell 
line that does not express Bim, the Bim level were downregulated in response to sorafenib, 
indicating that Bim is not a mediator of sorafenib-induced cell death. Udi et al. and 
Ramakrishnan et al. have also showed decrease in ERK phosphorylation in other myeloma cell 
lines (109, 110).  
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Mcl-1 has been shown to be an important survival factor for multiple myeloma (264). The 
cytoprotective effect of the Ras/Raf/MEK/ERK signaling cascade is partly mediated by the 
inhibition of degradation and subsequent stabilization of Mcl-1 proteins levels. Mcl-1 protein 
level were downregulated in all myeloma cell lines and did not change by using a MEK 
inhibitor, U0126. This indicates that the observed Mcl-1 downregulation by sorafenib is 
independent of the Ras/Raf/MEK/ERK pathway.  
Sorafenib induced cell death in freshly isolated CD138+ multiple myeloma cells from newly 
diagnosed patients. To mimic the bone marrow microenvironment effect, we co-cultured 
myeloma cells with BMSCs. BMSC were not found to exert any effect on sorafenib-induced 
cell death in U-266 cells but were protective in RPMI-8226 and potentiating cell death in OPM-
2 cells. Sorafenib was very potent in inducing cell death in all of the patient samples. While 
BMSCs cells protected the CD138+ primary multiple myeloma cells from spontaneous cell 
death in the co-culture setting, primary cells, when cultured, were still sensitive to sorafenib 
treatment.  
In line with the ability of sorafenib to potently downregulate Mcl-1 protein levels, we found 
that the combination of sorafenib with the Bcl-2 antagonist, ABT-737, potentiates sorafenib-
induced cell death on some cell lines and even overcomes BMSC protection in RPMI-8226 
cells. This combination is also very effective in patient samples. We also demonstrated that 
sorafenib is effective in both a bortezomib resistant cell line and primary samples.  
We further investigated the effect of sorafenib in the 5T33MM myeloma mouse model in 
collaboration with Professor Karin Vanderkerken at Vrije Universiteit Brussel. Mice treated 
with either sorafenib (60 mg/kg oral gavage daily) or vehicle for three weeks. Mice treated with 
sorafenib showed significantly increased survival, reduced tumor growth and decreased serum 
M component. Treatment with sorafenib significantly decreased microvessel density by 60% 
in the bone marrow of treated 5T33MMvv mouse, compared with vehicle-treated mice. No 
adverse side effects or toxicity were observed as evaluated by behavior, body weight, 
histologic, and hematologic examinations. Sorafenib was also found to inhibit ERK1/2 
phosphorylation, induced caspase activation and autophagy in multiple myeloma cells isolated 
from the bone marrow of the 5T33MM mice. 
 
Paper II: Sorafenib induces apoptosis and autophagy in prostate cancer cells in vitro 
The activation of both receptor tyrosine kinases (RTK) and that of nonreceptor tyrosine kinases 
(NRTK), such as Src and LCK, has been well described. Because of the critical role of RTK 
and NRTK in prostate cancer, they constitute prospective therapeutic targets. Sorafenib, a 
multi-tyrosine kinase inhibitor maybe a potentiate drug that can be used in prostate cancer 
treatment.  
We demonstrated that incubation with sorafenib for 72 h caused a dose-dependent decrease in 
cell viability in two hormone refractory (PC3 and DU145) and one hormone responsive 
(22Rv1) prostate cancer cell lines. While 22Rv1 was the most sensitive cell line, DU145 cells 
showed an intermediate sensitivity and PC3 cells were the least sensitive. Sorafenib decreases 
mitochondrial membrane potential (ΔΨm) in all cell lines and induces apoptosis. 
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Overexpressing the anti-apoptotic Bcl-2 protein in DU145 cells inhibits sorafenib-induced 
apoptosis. We also demonstrated that sorafenib induces autophagy and inhibits ERK 
phosphorylation in these prostate cancer cell lines.  
 
Paper III: Targeting of distinct signaling cascades and cancer-associated fibroblasts 
define the efficacy of Sorafenib against prostate cancer cells 
Following the demonstration that sorafenib is effective in prostate cancer, we investigate the 
mechanisms that sorafenib is effective against prostate cancer cell liens. 
In this study we investigated the mechanisms of sorafenib induced cell death in non-metastatic 
(22Rv1) and metastatic (PC3) prostate cancer cell lines, showing that 22Rv1 cells are more 
sensitive than PC3 cells. Treatment with sorafenib induced a modest decrease in mitochondrial 
membrane potential (ΔΨm) in 22Rv1 but almost complete decrease in PC3. Activation of 
caspases, cleavage of Bax and PARP and processing of AIF are seen in 22Rv1 after treatment 
with sorafenib but in PC3, there was only a small increase in active caspase-7 and PARP 
cleavage after treatment.  
We determined whether and to which extent sorafenib might mediate its pro-apoptotic action 
by inhibiting the Ras/Raf/MEK/ERK pathway. In 22Rv1 ERK1/2 is constitutively 
phosphorylated but not in PC3 and consequently Sorafenib can only inhibit ERK activation in 
22Rv1 cells. Chemically inhibition of MEK1 with U0126 by itself induced cell death in 22Rv1 
cells. Constitutive activation of MEK1 by MEK1 overexpression with a MEK1-DD construct, 
attenuated the Sorafenib-induced inhibition of ERK1/2 phosphorylation and Bad 
dephosphorylation. However it did not alter Sorafenib-induced Mcl-1 downregulation and 
cleavage. MEK1-DD overexpression significantly inhibited Sorafenib-induced cell death in 
22Rv1 cells. These data suggest that 22Rv1 cells require an active Ras/Raf/MEK/ERK 
pathway to survive and interrupting this pathway by sorafenib leads to the activation of Bad 
and consequent cell killing. Oh et al. has also shown decrease in ERK phosphorylation in 
22Rv1 and LNCaP cell lines (120). 
In PC3 cells, PTEN is not expressed leading to an uninhibited and constitutively active 
PI3K/AKT pathway. However, sorafenib inhibits phosphorylation of Src and AKT in PC3 
cells. On the other hand overexpression of constitutively active AKT construct protects PC3 
from sorafenib-induced cell death. Knockdown of Bim partially protected PC3 cells from 
sorafenib-induced killing, supporting an involvement of the PI3K/AKT/Bim axis in Sorafenib-
mediated PC3 cell death. Oh et al has also reported the similar finding (120). 
Treatment of 22Rv1 and PC3 with sorafenib induces LC3 lipidation, p62 degradation, and 
LC3-GFP+ cytoplasmic foci formation, all of which are characteristics of autophagy. Transient 
knockdown of Atg5 in 22Rv1 and PC3 leads to potentiation of sorafenib-induced cell death 
that confirms the cytoprotective role of autophagy in this context.  
Sorafenib downregulates Mcl-1 in a time and dose-dependent manner and co-treatment of with 
sorafenib and ABT737 significantly improved the efficacy of the therapy. On the other hand 
overexpression of Mcl-1 has a protective effect against Sorafenib. These data indicate that the 
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anti-apoptotic Bcl-2 family members Mcl-1, Bcl-2 and Bcl-xL protect prostate cancer cells 
from sorafenib-induced cell death.  
Co-culture of PC3 and 22Rv1 with CAFs protect them against sorafenib induced cell death. 
However, treatment with sorafenib plus ABT737 re-established the sensitivity of 22Rv1 and 
PC3 cells to cell killing in spite of the presence of CAFs. As it has been mentioned before, 
22Rv1 cells require an active Ras/Raf/MEK/ERK pathway to survive and that interrupting this 
pathway by sorafenib leads to the activation of Bad and consequent cell death. The presence of 
CAFs prevents the sorafenib-induced inhibition of ERK1/2 phosphorylation in 22Rv1 cells. In 
PC3 cells AKT phosphorylation is decreased after sorafenib treatment which leads to cell death 
but AKT phosphorylation and Bcl-xL protein levels were sustained in the presence of CAFs, 
thus providing survival signals for PC3 to resist sorafenib-induced cell death. 
 
Paper IV: Atg5-independent autophagy promotes sorafenib-induced necroptosis 
During studying the role of autophagy in sorafenib-induce cell death in prostate cancer cell 
lines, we found that autophagy is cytoprotective in PC3 and 22Rv1cell lines but it is cytotoxic 
in DU145 cell line.  
In this study we found that the DU145 cell line does not express ATG5, which is necessary for 
LC3 lipidation. Despite the lack of Atg5 expression in DU145 cells, treatment with sorafenib 
induces autophagy and revealed intracellular structures characteristic of autophagosomes. 
Formation of LC3-GFP+ foci and RFP foci in stably transfected DU145 with LC3-GFP and 
LC3-GFP-RFP respectively, are evidences for induction of Atg5-independent autophagy. We 
showed the similar effect in MEF Atg5-/- cells treated with Sorafenib. We found that neither 
the pancaspase inhibitor zVAD.fmk nor the caspase-9 inhibitor LEHD.fmk could block 
sorafenib induced cell death. We could not detect caspase-3 activity or cleavage of the caspase 
substrate PARP in DU145 cells treated with sorafenib. Moreover, there were no changes 
observed in Bak, Bax, Bcl-xL and AIF protein levels, nor could any activation of Bak and Bax 
be detected.  
Knockdown of ULK1 in DU145 cells leads to a potent decrease of sorafenib-induced cell death. 
Furthermore, stable transfection of DU145 cells with Beclin 1 shRNA constructs protected 
these cells from sorafenib-induced cell death. Importantly reconstitution of Atg5 expression in 
DU145 cells rescued them from sorafenib-induced cell death. Collectively these data 
demonstrate that sorafenib induced autophagy in DU145 cells is cytotoxic due to a lack of Atg5 
expression and either inhibition of early autophagy or restoration of Atg5 expression protects 
the cells from sorafenib-induced cell death. 
Treatment of DU145 cells with the RIPK1 inhibitor, necrostatin 1 (Nec1), or transient 
knockdown of RIPK1, inhibited sorafenib-induced cell death but had no effect in PC3 cells, 
which undergoes a caspase-dependent cell death. Importantly, ectopic expression of Atg5 in 
DU145 cells also protected from sorafenib-induced cell death and co-treatment with necrostatin 
1 did not further inhibit cell death. Immunocytochemical staining and proximity ligation assay 
(PLA) of DU145 cells for p62 and RIPK1 revealed that upon treatment with sorafenib there is 
an increase in co-localization between these two proteins. Knocking down of p62 in DU145 
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cells decreased the basal levels of RIPK1 protein suggesting that p62 protects RIPK1 from 
degradation. These data indicate that the lack of Atg5 expression is important for the activation 
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4. Conclusions and Future perspectives 
Paper I:  
Sorafenib alone or in combination with other chemicals like the Bcl-2/Bcl-xL antagonist 
(ABT737) or early or late stage autophagy inhibitors (3MA and chloroquine) is cytotoxic in 
multiple myeloma cell lines, primary human myeloma samples, mouse myeloma model and 
even both bortezomib resistant cell line and patient sample. 
Paper II: 
Sorafenib induces autophagy and apoptosis in prostate cancer cell lines. 
Paper III: 
Despite differential downstream signaling pathways activated in prostate cancer cell lines, 
sorafenib can induce apoptosis in both a hormone refractory (PC3) and a hormone responsive 
cell line (22Rv1). Cytoprotective autophagy was detected after sorafenib treatment of prostate 
cancer cell lines which shows important role of autophagy in the efficacy of anti-cancer 
treatment. Mcl-1 inactivation is further required for sorafenib-induced cell death. Co-treatment 
with ABT737 significantly increased sorafenib efficacy, and this combination can overcome 
the protective effect of the microenvironment in prostate cancer. 
 Paper IV: 
Sorafenib can induce necroptosis in Atg5-deficient prostate cancer cell line. In this case 
autophagy is cytotoxic and co-treatment with an autophagy inducer may increases the efficacy 
of sorafenib. 
In these translational studies, we found that sorafenib is effective in multiple myeloma in 
different modalities. Since sorafenib is used in clinic and we showed that it is effective not only 
in multiple myeloma cell lines and patient samples but also in myeloma mouse model, our 
finding provides a good rational to use sorafenib in clinical trial. Sorafenib can be used as a 
single agent or with combinational therapy based on individual characteristic of myeloma 
patient. 
We need further investigation to determine the upstream targets of sorafenib in prostate cancer 










This thesis is the result of around five years of reading, thinking, running different experiment, 
challenging, repeating, optimizing, interpreting the result, repeating again and again, success 
and mistakes, writing, disappointment, hope and the most important of all connecting with 
great people especially in department of oncology-pathology. I want to express my sincere 
gratitude to all the people that I have met or been working with during my PhD study at the 
department of oncology-pathology. 
I would like to say my thanks to my main supervisor Docent Theocharis Panaretakis for the 
opportunity to do my PhD in his lab and helping me to prepare my thesis. My co-supervisor 
Professor Dan Grandér, which helped me generously to come to Sweden. I started my studies 
on cancer in his lab around 6 years ago and I have learned many things from him. As I heard 
from others and experienced myself many times, he is a real problem solver not only in science 
but also in personal problems. During these years every time I needed help, he is the first person 
that I trust and believe that he has the solution. His great personality and leadership make 
everything tolerable in the department. His teaching technique is unique. I hope I will stay for 
my postdoc in the department and learn more from him. My co-supervisor Professor Sten 
Nilsson which I learned a lot about prostate cancer from him and I hope learn more in the 
future. And my former co-supervisor Professor Boris Zhivotovsky, which I have never been 
participating in a course better than his course on apoptosis. He defines everything patiently 
and nobody becomes tired when listening to Boris even for hours. His course was the only 
course that I wished that never reaches the end. I learned a lot also in blue group meeting group 
on Tuesdays in IMM which Boris leads.  
I have great opportunity to work in the same place that great scientists work and I learn a lot 
directly and indirectly. Professor Arne Östman, Docent Bertrand Joseph whose scientific 
achievement especially during recent years have been encouraging for junior scientists, 
Professor Lars Holmgren the former PhD student director, Docent Andreas Lundqvist the 
current PhD student director, Docent Marianne Farnebo who she is one of the most talented 
scientist I have ever met, Docent Angelo De Milito, which I hope to work with in future, 
Docent Katja Pokrovskaja Tamm who taught me many techniques when I came to the 
department, Docent Maria Shoshan and also Docent Svetlana Bajalica Lagercrantz, whose 
group I will hopefully join for my postdoc right after my dissertation. 
Lotte who taught me many techniques when I came here and you always had time to help me. 
When I have problem in experiments, you are the first whom has the answer.  
Lena who helped me a lot in prostate cancer experiments and for teaching me Swedish. 
I want to say my special gratitude to three friends, Ali for the great time we have both at work 
and outside. You are a great man and because of your friendship I don’t feel that I am far from 
home. Also for the long night that you stayed awake and went through my thesis and help me 
to edit and revise it. Claire who is working as postdoc in our group. For great time that we 
  61 
have at work and lunch time. I will miss you at my dissertation, however we are in the 
communication era, maybe we can set up a webcam contact during the dissertation. And my 
dear colleague and Swedish teacher Sophia, whom we had a lot of adventures in tackling the 
problems. Even now that you are far from us, still you are helping me with drawing figures and 
designing the cover of my thesis. You did a great job and I wish all the best for you in your 
new group and life. I recommend everyone who needs scientific figures to talk with you first.  
Thanks also to former member of the group Patricia, Sebastian, Georgia, Maria and of 
course Qiao that I never forget her. I wish you the best in your future life. 
Neither would my study have been possible without co-authors of the publications. I want to 
say my thanks to all co-authors that I have not mentioned before for their great contribution in 
the publications. 
Hendrik De Raeve, Charlotte Fristedt, Vladimir Gogvadze, Astrid Gruber, Edward 
Laane, Anders Österborg, Helena Jernberg-Wiklund, Fredrik Celsing, Karin 
Vanderkerken, Anders Ullén, Lena Thyrell, Lars Egevad, Peter Wiklund, Guido 
Kroemer.  
I want to also say special thanks to Anna-Maria, the Queen, for lunch discussions and being 
a good friend. I hope you find a position and continue with your PhD.  
I also would like to say some words with about other people in the department or other 
departments, being friend with you made my PhD easier than I expected. I hope I will stay at 
Karolinska Institutet for my postdoc and still enjoy communicating with you. Here I want to 
send my regards to Mehdi, Sara, Kaveh, Amir, Omid, Mohammad, Hanif, Fariba, Hamid, 
Shahab, Per, Sofia , Martin, Johanna, Jens, My, Zheng, Linda, Mikael, Carolina, Ma, 
Lisa, Marianne, Rainer, Iulian, Iryna, Miguel, Edel, Linda, Erik, Sebastian, Lina, 
Naveen, Xianli, Satar, Hojir, Markus, Jeroen, Janna, Helene, Elin, Carina, Paola, Mao, 
Christos, Elizabeth, Matheus, Jason, Pinelopi, Ghazal, Shiva, Emma, Sanaz, Salah and 
Reza. 
I also want to express my appreciation to some people who are working behind the scene and 
without their help nothing goes forward. Anne, Maria, Monica, Erika, Elle, Elisabeth, 
Sören, Eva-Lena, Ann-Gitt and Juan. 
I also want to thank my family and friends outside the lab. Iman, Sima, Sam, Shirin, Afshin, 
Nasim, Hossein, Soudabeh, Maral, Azadeh for their great help and warm-heart and kindness. 
My parents Mohammad Hossein and Sedigheh and my brother, Shahram and my sister, Mona 
for your endless support during these years that I have been in Sweden. 
My son, Parham that many times that you needed me, I was busy with my academic stuff and 
I miss your childhood time, even this summer with very nice weather I had to go to library and 
write my thesis instead of spending some time with you. 
 62 
And finally my wife Ghazaleh that without your support I could never manage to come to 
Sweden and start my PhD. This is a long way and you took the difficult part to take care of 

























  63 
6. References 
1. OECD (2010) Organisation for Economic Cooperation and Development (OECD) ,Cancer 
Incidence (OECD Publishing). 
2. Weinberg RA (2014) The biology of cancer  Second edition. Ed pp xx, 875 pages. 
3. Hanahan D & Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 
144(5):646-674. 
4. Steiner H, et al. (2004) An autocrine loop for vascular endothelial growth factor is 
established in prostate cancer cells generated after prolonged treatment with interleukin 
6. European journal of cancer 40(7):1066-1072. 
5. Verdelli D, et al. (2014) Molecular events underlying interleukin-6 independence in a 
subclone of the CMA-03 multiple myeloma cell line. Genes, chromosomes & cancer 
53(2):154-167. 
6. Tsubaki M, et al. (2013) Inhibition of the tumour necrosis factor-alpha autocrine loop 
enhances the sensitivity of multiple myeloma cells to anticancer drugs. European journal 
of cancer 49(17):3708-3717. 
7. Cai CQ, et al. (2008) Epidermal growth factor receptor activation in prostate cancer by 
three novel missense mutations. Oncogene 27(22):3201-3210. 
8. Romagnoli M, et al. (2007) Significant impact of survivin on myeloma cell growth. 
Leukemia 21(5):1070-1078. 
9. Kerr JF, Wyllie AH, & Currie AR (1972) Apoptosis: a basic biological phenomenon with 
wide-ranging implications in tissue kinetics. British journal of cancer 26(4):239-257. 
10. Fendler A, et al. (2013) The antiapoptotic function of miR-96 in prostate cancer by 
inhibition of FOXO1. PloS one 8(11):e80807. 
11. Teitz T, et al. (2000) Caspase 8 is deleted or silenced preferentially in childhood 
neuroblastomas with amplification of MYCN. Nature medicine 6(5):529-535. 
12. Wong RS (2011) Apoptosis in cancer: from pathogenesis to treatment. Journal of 
experimental & clinical cancer research : CR 30:87. 
13. Kumar V, Abbas AK, Aster JC, & Robbins SL (2013) Robbins basic pathology 
(Elsevier/Saunders, Philadelphia, PA) 9th Ed p p. 
14. Hayflick L & Moorhead PS (1961) The serial cultivation of human diploid cell strains. 
Experimental cell research 25:585-621. 
15. Raica M, Cimpean AM, & Ribatti D (2009) Angiogenesis in pre-malignant conditions. 
European journal of cancer 45(11):1924-1934. 
16. Fang J, et al. (2005) Apigenin inhibits VEGF and HIF-1 expression via PI3K/AKT/p70S6K1 
and HDM2/p53 pathways. FASEB journal : official publication of the Federation of 
American Societies for Experimental Biology 19(3):342-353. 
17. Nguyen DX, Bos PD, & Massague J (2009) Metastasis: from dissemination to organ-specific 
colonization. Nature reviews. Cancer 9(4):274-284. 
18. Warburg O (1956) On the origin of cancer cells. Science 123(3191):309-314. 
19. Alberts B (2008) Molecular biology of the cell (Garland Science, New York) 5th Ed. 
20. Craig NL (2010) Molecular biology : principles of genome function (Oxford University Press, 
Oxford ; New York) pp xli, 839 p. 
21. Jacob T, Van den Broeke C, & Favoreel HW (2011) Viral serine/threonine protein kinases. 
Journal of virology 85(3):1158-1173. 
22. Vlahovic G & Crawford J (2003) Activation of tyrosine kinases in cancer. The oncologist 
8(6):531-538. 
23. Hubbard SR & Till JH (2000) Protein tyrosine kinase structure and function. Annual review 
of biochemistry 69:373-398. 
24. Katz G, Krummey SM, Larsen SE, Stinson JR, & Snow AL (2014) SAP facilitates recruitment 
and activation of LCK at NTB-A receptors during restimulation-induced cell death. Journal 
of immunology 192(9):4202-4209. 
25. Hao QL, Ferris DK, White G, Heisterkamp N, & Groffen J (1991) Nuclear and cytoplasmic 
location of the FER tyrosine kinase. Molecular and cellular biology 11(2):1180-1183. 
 64 
26. Wang JY (2014) The capable ABL: what is its biological function? Molecular and cellular 
biology 34(7):1188-1197. 
27. Alvarez RH, Kantarjian HM, & Cortes JE (2006) The role of Src in solid and hematologic 
malignancies: development of new-generation Src inhibitors. Cancer 107(8):1918-1929. 
28. Chang YM, Kung HJ, & Evans CP (2007) Nonreceptor tyrosine kinases in prostate cancer. 
Neoplasia 9(2):90-100. 
29. Berridge MJ (2012) Cell Signalling Biology. 
30. Frame MC (2002) Src in cancer: deregulation and consequences for cell behaviour. 
Biochimica et biophysica acta 1602(2):114-130. 
31. Bjorge JD, Jakymiw A, & Fujita DJ (2000) Selected glimpses into the activation and function 
of Src kinase. Oncogene 19(49):5620-5635. 
32. Kim LC, Song L, & Haura EB (2009) Src kinases as therapeutic targets for cancer. Nature 
reviews. Clinical oncology 6(10):587-595. 
33. Khusial PR, et al. (2010) Src activates Abl to augment Robo1 expression in order to 
promote tumor cell migration. Oncotarget 1(3):198-209. 
34. Araujo JC, et al. (2009) Dasatinib inhibits both osteoclast activation and prostate cancer 
PC-3-cell-induced osteoclast formation. Cancer biology & therapy 8(22):2153-2159. 
35. Yang G, et al. (2009) Proteomic, functional and motif-based analysis of C-terminal Src 
kinase-interacting proteins. Proteomics 9(21):4944-4961. 
36. Okada M (2012) Regulation of the SRC family kinases by Csk. International journal of 
biological sciences 8(10):1385-1397. 
37. Greuber EK, Smith-Pearson P, Wang J, & Pendergast AM (2013) Role of ABL family kinases 
in cancer: from leukaemia to solid tumours. Nature reviews. Cancer 13(8):559-571. 
38. Mitra SK, Hanson DA, & Schlaepfer DD (2005) Focal adhesion kinase: in command and 
control of cell motility. Nature reviews. Molecular cell biology 6(1):56-68. 
39. Schlaepfer DD, Hauck CR, & Sieg DJ (1999) Signaling through focal adhesion kinase. 
Progress in biophysics and molecular biology 71(3-4):435-478. 
40. Condorelli F, et al. (2011) Role of the non-receptor tyrosine kinase fes in cancer. Current 
medicinal chemistry 18(19):2913-2920. 
41. Rawlings JS, Rosler KM, & Harrison DA (2004) The JAK/STAT signaling pathway. Journal of 
cell science 117(Pt 8):1281-1283. 
42. Seidel HM, Lamb P, & Rosen J (2000) Pharmaceutical intervention in the JAK/STAT 
signaling pathway. Oncogene 19(21):2645-2656. 
43. Shuai K & Liu B (2003) Regulation of JAK-STAT signalling in the immune system. Nature 
reviews. Immunology 3(11):900-911. 
44. Mocsai A, Ruland J, & Tybulewicz VL (2010) The SYK tyrosine kinase: a crucial player in 
diverse biological functions. Nature reviews. Immunology 10(6):387-402. 
45. Koprulu AD & Ellmeier W (2009) The role of Tec family kinases in mononuclear 
phagocytes. Critical reviews in immunology 29(4):317-333. 
46. Prieto-Echague V, Gucwa A, Craddock BP, Brown DA, & Miller WT (2010) Cancer-
associated mutations activate the nonreceptor tyrosine kinase Ack1. The Journal of 
biological chemistry 285(14):10605-10615. 
47. Gschwind A, Fischer OM, & Ullrich A (2004) The discovery of receptor tyrosine kinases: 
targets for cancer therapy. Nature reviews. Cancer 4(5):361-370. 
48. Robinson DR, Wu YM, & Lin SF (2000) The protein tyrosine kinase family of the human 
genome. Oncogene 19(49):5548-5557. 
49. Lemmon MA & Schlessinger J (2010) Cell signaling by receptor tyrosine kinases. Cell 
141(7):1117-1134. 
50. Ward CW, Lawrence MC, Streltsov VA, Adams TE, & McKern NM (2007) The insulin and 
EGF receptor structures: new insights into ligand-induced receptor activation. Trends in 
biochemical sciences 32(3):129-137. 
51. Rini BI & Small EJ (2005) Biology and clinical development of vascular endothelial growth 
factor-targeted therapy in renal cell carcinoma. Journal of clinical oncology : official journal 
of the American Society of Clinical Oncology 23(5):1028-1043. 
  65 
52. Vincenti V, Cassano C, Rocchi M, & Persico G (1996) Assignment of the vascular 
endothelial growth factor gene to human chromosome 6p21.3. Circulation 93(8):1493-
1495. 
53. Ferrara N & Henzel WJ (1989) Pituitary follicular cells secrete a novel heparin-binding 
growth factor specific for vascular endothelial cells. Biochemical and biophysical research 
communications 161(2):851-858. 
54. Turner N & Grose R (2010) Fibroblast growth factor signalling: from development to 
cancer. Nature reviews. Cancer 10(2):116-129. 
55. Parker BC, Engels M, Annala M, & Zhang W (2014) Emergence of FGFR family gene fusions 
as therapeutic targets in a wide spectrum of solid tumours. The Journal of pathology 
232(1):4-15. 
56. Katoh M & Nakagama H (2014) FGF receptors: cancer biology and therapeutics. Medicinal 
research reviews 34(2):280-300. 
57. Chesi M, et al. (1997) Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is 
associated with increased expression and activating mutations of fibroblast growth factor 
receptor 3. Nature genetics 16(3):260-264. 
58. Ronca R, et al. (2013) Long pentraxin-3 as an epithelial-stromal fibroblast growth factor-
targeting inhibitor in prostate cancer. The Journal of pathology 230(2):228-238. 
59. Yagasaki F, et al. (2001) Fusion of ETV6 to fibroblast growth factor receptor 3 in peripheral 
T-cell lymphoma with a t(4;12)(p16;p13) chromosomal translocation. Cancer research 
61(23):8371-8374. 
60. Salazar L, et al. (2014) Fibroblast growth factor receptor 3 interacts with and activates 
TGFbeta-activated kinase 1 tyrosine phosphorylation and NFkappaB signaling in multiple 
myeloma and bladder cancer. PloS one 9(1):e86470. 
61. Baselga J (2002) Why the epidermal growth factor receptor? The rationale for cancer 
therapy. The oncologist 7 Suppl 4:2-8. 
62. Heldin CH & Lennartsson J (2013) Structural and functional properties of platelet-derived 
growth factor and stem cell factor receptors. Cold Spring Harbor perspectives in biology 
5(8):a009100. 
63. Heldin CH (2013) Targeting the PDGF signaling pathway in tumor treatment. Cell 
communication and signaling : CCS 11:97. 
64. Demoulin JB & Essaghir A (2014) PDGF receptor signaling networks in normal and cancer 
cells. Cytokine & growth factor reviews 25(3):273-283. 
65. Cao Y, Cao R, & Hedlund EM (2008) R Regulation of tumor angiogenesis and metastasis by 
FGF and PDGF signaling pathways. Journal of molecular medicine 86(7):785-789. 
66. Shah S, Loghavi S, Garcia-Manero G, & Khoury JD (2014) Discovery of imatinib-responsive 
FIP1L1-PDGFRA mutation during refractory acute myeloid leukemia transformation of 
chronic myelomonocytic leukemia. Journal of hematology & oncology 7:26. 
67. Hartmann K, et al. (2005) Novel germline mutation of KIT associated with familial 
gastrointestinal stromal tumors and mastocytosis. Gastroenterology 129(3):1042-1046. 
68. Montero JC, Lopez-Perez R, San Miguel JF, & Pandiella A (2008) Expression of c-Kit 
isoforms in multiple myeloma: differences in signaling and drug sensitivity. Haematologica 
93(6):851-859. 
69. Swords R, Freeman C, & Giles F (2012) Targeting the FMS-like tyrosine kinase 3 in acute 
myeloid leukemia. Leukemia 26(10):2176-2185. 
70. Beffinger M & Skwarska A (2012) The role of FLT3 kinase as an AML therapy target. Current 
pharmaceutical design 18(19):2758-2765. 
71. Malaguarnera R & Belfiore A (2014) The emerging role of insulin and insulin-like growth 
factor signaling in cancer stem cells. Frontiers in endocrinology 5:10. 
72. Baxter RC (2014) IGF binding proteins in cancer: mechanistic and clinical insights. Nature 
reviews. Cancer 14(5):329-341. 
73. Janssen JA & Varewijck AJ (2014) Insulin analogs and cancer: a note of caution. Frontiers in 
endocrinology 5:79. 
 66 
74. LeRoith D & Roberts CT, Jr. (2003) The insulin-like growth factor system and cancer. Cancer 
letters 195(2):127-137. 
75. Moschos SJ & Mantzoros CS (2002) The role of the IGF system in cancer: from basic to 
clinical studies and clinical applications. Oncology 63(4):317-332. 
76. Arighi E, Borrello MG, & Sariola H (2005) RET tyrosine kinase signaling in development and 
cancer. Cytokine & growth factor reviews 16(4-5):441-467. 
77. Phay JE & Shah MH (2010) Targeting RET receptor tyrosine kinase activation in cancer. 
Clinical cancer research : an official journal of the American Association for Cancer 
Research 16(24):5936-5941. 
78. Vivanco I & Sawyers CL (2002) The phosphatidylinositol 3-Kinase AKT pathway in human 
cancer. Nature reviews. Cancer 2(7):489-501. 
79. Okkenhaug K & Vanhaesebroeck B (2003) PI3K in lymphocyte development, differentiation 
and activation. Nature reviews. Immunology 3(4):317-330. 
80. Jiang BH & Liu LZ (2009) PI3K/PTEN signaling in angiogenesis and tumorigenesis. Advances 
in cancer research 102:19-65. 
81. Steelman LS, et al. (2004) JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle 
progression and leukemogenesis. Leukemia 18(2):189-218. 
82. Gartel AL & Radhakrishnan SK (2005) Lost in transcription: p21 repression, mechanisms, 
and consequences. Cancer research 65(10):3980-3985. 
83. Rossig L, et al. (2001) Akt-dependent phosphorylation of p21(Cip1) regulates PCNA binding 
and proliferation of endothelial cells. Molecular and cellular biology 21(16):5644-5657. 
84. Wullschleger S, Loewith R, & Hall MN (2006) TOR signaling in growth and metabolism. Cell 
124(3):471-484. 
85. Munshi NC & Anderson KC (Advances in biology and therapy of multiple myeloma  p 
volumes. 
86. Hennessy BT, Smith DL, Ram PT, Lu Y, & Mills GB (2005) Exploiting the PI3K/AKT pathway 
for cancer drug discovery. Nature reviews. Drug discovery 4(12):988-1004. 
87. Huntzinger E & Izaurralde E (2011) Gene silencing by microRNAs: contributions of 
translational repression and mRNA decay. Nature reviews. Genetics 12(2):99-110. 
88. Charlesworth A, Meijer HA, & de Moor CH (2013) Specificity factors in cytoplasmic 
polyadenylation. Wiley interdisciplinary reviews. RNA 4(4):437-461. 
89. Vogel S, et al. (2006) MEK hyperphosphorylation coincides with cell cycle shut down of 
cultured smooth muscle cells. Journal of cellular physiology 206(1):25-34. 
90. Roskoski R, Jr. (2012) ERK1/2 MAP kinases: structure, function, and regulation. 
Pharmacological research : the official journal of the Italian Pharmacological Society 
66(2):105-143. 
91. Sebolt-Leopold JS & Herrera R (2004) Targeting the mitogen-activated protein kinase 
cascade to treat cancer. Nature reviews. Cancer 4(12):937-947. 
92. Chase JL (2008) Clinical use of anti-vascular endothelial growth factor monoclonal 
antibodies in metastatic colorectal cancer. Pharmacotherapy 28(11 Pt 2):23S-30S. 
93. Nahta R, Yu D, Hung MC, Hortobagyi GN, & Esteva FJ (2006) Mechanisms of disease: 
understanding resistance to HER2-targeted therapy in human breast cancer. Nature 
clinical practice. Oncology 3(5):269-280. 
94. Liu Y & Gray NS (2006) Rational design of inhibitors that bind to inactive kinase 
conformations. Nature chemical biology 2(7):358-364. 
95. Zhang J, Yang PL, & Gray NS (2009) Targeting cancer with small molecule kinase inhibitors. 
Nature reviews. Cancer 9(1):28-39. 
96. Blanchet B, et al. (2010) Toxicity of sorafenib: clinical and molecular aspects. Expert 
opinion on drug safety 9(2):275-287. 
97. Wilhelm S, et al. (2006) Discovery and development of sorafenib: a multikinase inhibitor 
for treating cancer. Nature reviews. Drug discovery 5(10):835-844. 
98. Limited BNZ (April 2014) Data Sheet NEXAVAR® Sorafenib tosylate Tablets, film-coated 200 
mg. 
  67 
99. Goodman LS, Brunton LL, Chabner B, & Knollmann BrC (2011) Goodman & Gilman's 
pharmacological basis of therapeutics (McGraw-Hill, New York) 12th Ed p 2084 p. 
100. Wan PT, et al. (2004) Mechanism of activation of the RAF-ERK signaling pathway by 
oncogenic mutations of B-RAF. Cell 116(6):855-867. 
101. Dietrich J, Hulme C, & Hurley LH (2010) The design, synthesis, and evaluation of 8 hybrid 
DFG-out allosteric kinase inhibitors: a structural analysis of the binding interactions of 
Gleevec, Nexavar, and BIRB-796. Bioorganic & medicinal chemistry 18(15):5738-5748. 
102. Bull VH, Rajalingam K, & Thiede B (2012) Sorafenib-induced mitochondrial complex I 
inactivation and cell death in human neuroblastoma cells. Journal of proteome research 
11(3):1609-1620. 
103. Chiou JF, et al. (2009) Sorafenib induces preferential apoptotic killing of a drug- and radio-
resistant Hep G2 cells through a mitochondria-dependent oxidative stress mechanism. 
Cancer biology & therapy 8(20):1904-1913. 
104. FDA (2013) NEXAVAR (sorafenib) tablets, oral. Reference ID: 3411803 
 
105. Iyer R, Fetterly G, Lugade A, & Thanavala Y (2010) Sorafenib: a clinical and pharmacologic 
review. Expert opinion on pharmacotherapy 11(11):1943-1955. 
106. Ye L, et al. (2014) Sorafenib metabolism is significantly altered in the liver tumor tissue of 
hepatocellular carcinoma patient. PloS one 9(5):e96664. 
107. Agency EM (2014) Nexavar -EMEA/H/C/000690 -II/0035. 
108. Kharaziha P, et al. (2012) Sorafenib has potent antitumor activity against multiple 
myeloma in vitro, ex vivo, and in vivo in the 5T33MM mouse model. Cancer research 
72(20):5348-5362. 
109. Ramakrishnan V, et al. (2010) Sorafenib, a dual Raf kinase/vascular endothelial growth 
factor receptor inhibitor has significant anti-myeloma activity and synergizes with common 
anti-myeloma drugs. Oncogene 29(8):1190-1202. 
110. Udi J, et al. (2013) Potent in vitro and in vivo activity of sorafenib in multiple myeloma: 
induction of cell death, CD138-downregulation and inhibition of migration through actin 
depolymerization. British journal of haematology 161(1):104-116. 
111. Ramirez-Labrada A, et al. (2014) Two death pathways induced by sorafenib in myeloma 
cells: Puma-mediated apoptosis and necroptosis. Clinical & translational oncology : official 
publication of the Federation of Spanish Oncology Societies and of the National Cancer 
Institute of Mexico. 
112. Srkalovic G, et al. (2014) A phase II trial of BAY 43-9006 (sorafenib) (NSC-724772) in 
patients with relapsing and resistant multiple myeloma: SWOG S0434. Cancer medicine. 
113. Kumar SK, et al. (2013) Phase 1 study of sorafenib in combination with bortezomib in 
patients with advanced malignancies. Investigational new drugs 31(5):1201-1206. 
114. Ullen A, et al. (2010) Sorafenib induces apoptosis and autophagy in prostate cancer cells in 
vitro. International journal of oncology 37(1):15-20. 
115. Kharaziha P, et al. (2012) Targeting of distinct signaling cascades and cancer-associated 
fibroblasts define the efficacy of Sorafenib against prostate cancer cells. Cell death & 
disease 3:e262. 
116. Huang R, Chen XQ, Huang Y, Chen N, & Zeng H (2010) The multikinase inhibitor sorafenib 
induces caspase-dependent apoptosis in PC-3 prostate cancer cells. Asian journal of 
andrology 12(4):527-534. 
117. Cyran CC, et al. (2012) Dynamic contrast-enhanced computed tomography imaging 
biomarkers correlated with immunohistochemistry for monitoring the effects of sorafenib 
on experimental prostate carcinomas. Investigative radiology 47(1):49-57. 
118. Cyran CC, et al. (2012) Perfusion MRI for monitoring the effect of sorafenib on 
experimental prostate carcinoma: a validation study. AJR. American journal of 
roentgenology 198(2):384-391. 
119. Cyran CC, et al. (2013) In vivo monitoring of sorafenib therapy effects on experimental 
prostate carcinomas using dynamic contrast-enhanced MRI and macromolecular contrast 
 68 
media. Cancer imaging : the official publication of the International Cancer Imaging Society 
13(4):557-566. 
120. Oh SJ, Erb HH, Hobisch A, Santer FR, & Culig Z (2012) Sorafenib decreases proliferation and 
induces apoptosis of prostate cancer cells by inhibition of the androgen receptor and Akt 
signaling pathways. Endocrine-related cancer 19(3):305-319. 
121. Dahut WL, et al. (2008) A phase II clinical trial of sorafenib in androgen-independent 
prostate cancer. Clinical cancer research : an official journal of the American Association 
for Cancer Research 14(1):209-214. 
122. Aragon-Ching JB, et al. (2009) Final analysis of a phase II trial using sorafenib for metastatic 
castration-resistant prostate cancer. BJU international 103(12):1636-1640. 
123. Mardjuadi F, et al. (2012) Phase I study of sorafenib in combination with docetaxel and 
prednisone in chemo-naive patients with metastatic castration-resistant prostate cancer. 
Cancer chemotherapy and pharmacology 70(2):293-303. 
124. Chi KN, et al. (2008) A phase II study of sorafenib in patients with chemo-naive castration-
resistant prostate cancer. Annals of oncology : official journal of the European Society for 
Medical Oncology / ESMO 19(4):746-751. 
125. Melino G & Vaux D (2010) Cell death (Wiley-Blackwell, Chichester, UK ; Hoboken, NJ) pp xi, 
303 p. 
126. van Delft MF & Huang DC (2006) How the Bcl-2 family of proteins interact to regulate 
apoptosis. Cell research 16(2):203-213. 
127. Youle RJ & Strasser A (2008) The BCL-2 protein family: opposing activities that mediate cell 
death. Nature reviews. Molecular cell biology 9(1):47-59. 
128. Ura S, Masuyama N, Graves JD, & Gotoh Y (2001) Caspase cleavage of MST1 promotes 
nuclear translocation and chromatin condensation. Proceedings of the National Academy 
of Sciences of the United States of America 98(18):10148-10153. 
129. Vucic D, Dixit VM, & Wertz IE (2011) Ubiquitylation in apoptosis: a post-translational 
modification at the edge of life and death. Nature reviews. Molecular cell biology 
12(7):439-452. 
130. Boatright KM & Salvesen GS (2003) Mechanisms of caspase activation. Current opinion in 
cell biology 15(6):725-731. 
131. Stassi G & De Maria R (2002) Autoimmune thyroid disease: new models of cell death in 
autoimmunity. Nature reviews. Immunology 2(3):195-204. 
132. Boivin WA, Cooper DM, Hiebert PR, & Granville DJ (2009) Intracellular versus extracellular 
granzyme B in immunity and disease: challenging the dogma. Laboratory investigation; a 
journal of technical methods and pathology 89(11):1195-1220. 
133. Vanden Berghe T, Linkermann A, Jouan-Lanhouet S, Walczak H, & Vandenabeele P (2014) 
Regulated necrosis: the expanding network of non-apoptotic cell death pathways. Nature 
reviews. Molecular cell biology 15(2):135-147. 
134. Vandenabeele P, Galluzzi L, Vanden Berghe T, & Kroemer G (2010) Molecular mechanisms 
of necroptosis: an ordered cellular explosion. Nature reviews. Molecular cell biology 
11(10):700-714. 
135. Yorimitsu T & Klionsky DJ (2005) Autophagy: molecular machinery for self-eating. Cell 
death and differentiation 12 Suppl 2:1542-1552. 
136. Ganley IG, Wong PM, Gammoh N, & Jiang X (2011) Distinct autophagosomal-lysosomal 
fusion mechanism revealed by thapsigargin-induced autophagy arrest. Molecular cell 
42(6):731-743. 
137. Maiuri MC, Zalckvar E, Kimchi A, & Kroemer G (2007) Self-eating and self-killing: crosstalk 
between autophagy and apoptosis. Nature reviews. Molecular cell biology 8(9):741-752. 
138. Ganley IG, et al. (2009) ULK1.ATG13.FIP200 complex mediates mTOR signaling and is 
essential for autophagy. The Journal of biological chemistry 284(18):12297-12305. 
139. Alers S, Loffler AS, Wesselborg S, & Stork B (2012) Role of AMPK-mTOR-Ulk1/2 in the 
regulation of autophagy: cross talk, shortcuts, and feedbacks. Molecular and cellular 
biology 32(1):2-11. 
  69 
140. Kim KH & Lee MS (2014) Autophagy--a key player in cellular and body metabolism. Nature 
reviews. Endocrinology 10(6):322-337. 
141. Russell RC, et al. (2013) ULK1 induces autophagy by phosphorylating Beclin-1 and 
activating VPS34 lipid kinase. Nature cell biology 15(7):741-750. 
142. Tooze SA & Yoshimori T (2010) The origin of the autophagosomal membrane. Nature cell 
biology 12(9):831-835. 
143. Wang RC, et al. (2012) Akt-mediated regulation of autophagy and tumorigenesis through 
Beclin 1 phosphorylation. Science 338(6109):956-959. 
144. Wei Y, et al. (2013) EGFR-mediated Beclin 1 phosphorylation in autophagy suppression, 
tumor progression, and tumor chemoresistance. Cell 154(6):1269-1284. 
145. Marino G, Niso-Santano M, Baehrecke EH, & Kroemer G (2014) Self-consumption: the 
interplay of autophagy and apoptosis. Nature reviews. Molecular cell biology 15(2):81-94. 
146. Xie Z & Klionsky DJ (2007) Autophagosome formation: core machinery and adaptations. 
Nature cell biology 9(10):1102-1109. 
147. Mizushima N, Noda T, & Ohsumi Y (1999) Apg16p is required for the function of the 
Apg12p-Apg5p conjugate in the yeast autophagy pathway. The EMBO journal 18(14):3888-
3896. 
148. Kuma A, Mizushima N, Ishihara N, & Ohsumi Y (2002) Formation of the approximately 350-
kDa Apg12-Apg5.Apg16 multimeric complex, mediated by Apg16 oligomerization, is 
essential for autophagy in yeast. The Journal of biological chemistry 277(21):18619-18625. 
149. Romanov J, et al. (2012) Mechanism and functions of membrane binding by the Atg5-
Atg12/Atg16 complex during autophagosome formation. The EMBO journal 31(22):4304-
4317. 
150. Gao W, Chen Z, Wang W, & Stang MT (2013) E1-like activating enzyme Atg7 is 
preferentially sequestered into p62 aggregates via its interaction with LC3-I. PloS one 
8(9):e73229. 
151. Levine B, Mizushima N, & Virgin HW (2011) Autophagy in immunity and inflammation. 
Nature 469(7330):323-335. 
152. Kirisako T, et al. (2000) The reversible modification regulates the membrane-binding state 
of Apg8/Aut7 essential for autophagy and the cytoplasm to vacuole targeting pathway. 
The Journal of cell biology 151(2):263-276. 
153. Birgisdottir AB, Lamark T, & Johansen T (2013) The LIR motif - crucial for selective 
autophagy. Journal of cell science 126(Pt 15):3237-3247. 
154. Kraft C, Peter M, & Hofmann K (2010) Selective autophagy: ubiquitin-mediated recognition 
and beyond. Nature cell biology 12(9):836-841. 
155. Pankiv S, et al. (2007) p62/SQSTM1 binds directly to Atg8/LC3 to facilitate degradation of 
ubiquitinated protein aggregates by autophagy. The Journal of biological chemistry 
282(33):24131-24145. 
156. Moreau K, Renna M, & Rubinsztein DC (2013) Connections between SNAREs and 
autophagy. Trends in biochemical sciences 38(2):57-63. 
157. Dimopoulos MA & Terpos E (2010) Multiple myeloma. Annals of oncology : official journal 
of the European Society for Medical Oncology / ESMO 21 Suppl 7:vii143-150. 
158. Kaushansky K & Williams WJ (2010) Williams hematology (McGraw-Hill Medical, New 
York) 8th Ed pp xxiii, 2439 p. 
159. Kyle RA & Rajkumar SV (2009) Criteria for diagnosis, staging, risk stratification and 
response assessment of multiple myeloma. Leukemia 23(1):3-9. 
160. Alexander DD, et al. (2007) Multiple myeloma: a review of the epidemiologic literature. 
International journal of cancer. Journal international du cancer 120 Suppl 12:40-61. 
161. Lentzsch S (2012) Genetic and molecular epidemiology of multiple myeloma (Springer, New 
York). 
162. Matsui W, et al. (2004) Characterization of clonogenic multiple myeloma cells. Blood 
103(6):2332-2336. 
163. Kuppers R, Klein U, Hansmann ML, & Rajewsky K (1999) Cellular origin of human B-cell 
lymphomas. The New England journal of medicine 341(20):1520-1529. 
 70 
164. Gonzalez D, et al. (2007) Immunoglobulin gene rearrangements and the pathogenesis of 
multiple myeloma. Blood 110(9):3112-3121. 
165. Walker BA, et al. (2013) Characterization of IGH locus breakpoints in multiple myeloma 
indicates a subset of translocations appear to occur in pregerminal center B cells. Blood 
121(17):3413-3419. 
166. Kuehl WM & Bergsagel PL (2002) Multiple myeloma: evolving genetic events and host 
interactions. Nature reviews. Cancer 2(3):175-187. 
167. Itoua Maiga R, Lemieux J, Roy A, Simard C, & Neron S (2014) Flow cytometry assessment 
of in vitro generated CD138+ human plasma cells. BioMed research international 
2014:536482. 
168. Anderson KC & Carrasco RD (2011) Pathogenesis of myeloma. Annual review of pathology 
6:249-274. 
169. Landgren O, et al. (2009) Monoclonal gammopathy of undetermined significance (MGUS) 
consistently precedes multiple myeloma: a prospective study. Blood 113(22):5412-5417. 
170. Wadhera RK & Rajkumar SV (2010) Prevalence of monoclonal gammopathy of 
undetermined significance: a systematic review. Mayo Clinic proceedings 85(10):933-942. 
171. Korde N, Kristinsson SY, & Landgren O (2011) Monoclonal gammopathy of undetermined 
significance (MGUS) and smoldering multiple myeloma (SMM): novel biological insights 
and development of early treatment strategies. Blood 117(21):5573-5581. 
172. Kyle RA, et al. (2010) Monoclonal gammopathy of undetermined significance (MGUS) and 
smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors 
for progression and guidelines for monitoring and management. Leukemia 24(6):1121-
1127. 
173. Kuehl WM & Bergsagel PL (2012) Molecular pathogenesis of multiple myeloma and its 
premalignant precursor. The Journal of clinical investigation 122(10):3456-3463. 
174. Bergsagel PL & Kuehl WM (2005) Molecular pathogenesis and a consequent classification 
of multiple myeloma. Journal of clinical oncology : official journal of the American Society 
of Clinical Oncology 23(26):6333-6338. 
175. Hideshima T, Mitsiades C, Tonon G, Richardson PG, & Anderson KC (2007) Understanding 
multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. 
Nature reviews. Cancer 7(8):585-598. 
176. Mahtouk K, et al. (2010) Growth factors in multiple myeloma: a comprehensive analysis of 
their expression in tumor cells and bone marrow environment using Affymetrix 
microarrays. BMC cancer 10:198. 
177. Sprynski AC, et al. (2009) The role of IGF-1 as a major growth factor for myeloma cell lines 
and the prognostic relevance of the expression of its receptor. Blood 113(19):4614-4626. 
178. Hose D, et al. (2009) Induction of angiogenesis by normal and malignant plasma cells. 
Blood 114(1):128-143. 
179. Sanderson RD & Yang Y (2008) Syndecan-1: a dynamic regulator of the myeloma 
microenvironment. Clinical & experimental metastasis 25(2):149-159. 
180. Kawano M, et al. (1988) Autocrine generation and requirement of BSF-2/IL-6 for human 
multiple myelomas. Nature 332(6159):83-85. 
181. Puthier D, Bataille R, & Amiot M (1999) IL-6 up-regulates mcl-1 in human myeloma cells 
through JAK / STAT rather than ras / MAP kinase pathway. European journal of 
immunology 29(12):3945-3950. 
182. Puthier D, et al. (1999) Mcl-1 and Bcl-xL are co-regulated by IL-6 in human myeloma cells. 
British journal of haematology 107(2):392-395. 
183. Heinrich PC, et al. (2003) Principles of interleukin (IL)-6-type cytokine signalling and its 
regulation. The Biochemical journal 374(Pt 1):1-20. 
184. Greiser JS, Stross C, Heinrich PC, Behrmann I, & Hermanns HM (2002) Orientational 
constraints of the gp130 intracellular juxtamembrane domain for signaling. The Journal of 
biological chemistry 277(30):26959-26965. 
185. Bolkun L, et al. (2014) BAFF and APRIL as TNF superfamily molecules and angiogenesis 
parallel progression of human multiple myeloma. Annals of hematology 93(4):635-644. 
  71 
186. Lemancewicz D, et al. (2013) Evaluation of TNF superfamily molecules in multiple myeloma 
patients: correlation with biological and clinical features. Leukemia research 37(9):1089-
1093. 
187. Moreaux J, et al. (2004) BAFF and APRIL protect myeloma cells from apoptosis induced by 
interleukin 6 deprivation and dexamethasone. Blood 103(8):3148-3157. 
188. Andrews SW, Kabrah S, May JE, Donaldson C, & Morse HR (2013) Multiple myeloma: the 
bone marrow microenvironment and its relation to treatment. British journal of 
biomedical science 70(3):110-120. 
189. Olechnowicz SW & Edwards CM (2014) Contributions of the host microenvironment to 
cancer-induced bone disease. Cancer research 74(6):1625-1631. 
190. Mohty M, et al. (2014) The effects of bortezomib on bone disease in patients with multiple 
myeloma. Cancer 120(5):618-623. 
191. Wang J, et al. (2014) Bone marrow stromal cell-derived exosomes as communicators in 
drug resistance in multiple myeloma cells. Blood. 
192. Liu Y, et al. (2014) Microvesicles secreted from human multiple myeloma cells promote 
angiogenesis. Acta pharmacologica Sinica 35(2):230-238. 
193. Sanz-Rodriguez F, Ruiz-Velasco N, Pascual-Salcedo D, & Teixido J (1999) Characterization of 
VLA-4-dependent myeloma cell adhesion to fibronectin and VCAM-1. British journal of 
haematology 107(4):825-834. 
194. Jakob C, et al. (2006) Angiogenesis in multiple myeloma. European journal of cancer 
42(11):1581-1590. 
195. Dankbar B, et al. (2000) Vascular endothelial growth factor and interleukin-6 in paracrine 
tumor-stromal cell interactions in multiple myeloma. Blood 95(8):2630-2636. 
196. Babarovic E, et al. (2012) Assessment of bone marrow fibrosis and angiogenesis in 
monitoring patients with multiple myeloma. American journal of clinical pathology 
137(6):870-878. 
197. Fei M, Hang Q, Hou S, & Ruan C (2013) Cell adhesion to fibronectin down-regulates the 
expression of Spy1 and contributes to drug resistance in multiple myeloma cells. 
International journal of hematology 98(4):446-455. 
198. Fei M, Hang Q, Hou S, He S, & Ruan C (2014) Adhesion to fibronectin induces p27(Kip1) 
nuclear accumulation through down-regulation of Jab1 and contributes to cell adhesion-
mediated drug resistance (CAM-DR) in RPMI 8,226 cells. Molecular and cellular 
biochemistry 386(1-2):177-187. 
199. Grimaud E, et al. (2003) Receptor activator of nuclear factor kappaB ligand 
(RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis. The American 
journal of pathology 163(5):2021-2031. 
200. Roodman GD (2009) Pathogenesis of myeloma bone disease. Leukemia 23(3):435-441. 
201. Fulciniti M, et al. (2009) Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for 
multiple myeloma. Blood 114(2):371-379. 
202. Gertz MA & Rajkumar SV (Multiple myeloma : diagnosis and treatment  pp xi, 311 pages. 
203. Nolan KD, Mone MC, & Nelson EW (2005) Plasma cell neoplasms. Review of disease 
progression and report of a new variant. Surgical oncology 14(2):85-90. 
204. Campbell RA, et al. (2006) LAGlambda-1: a clinically relevant drug resistant human 
multiple myeloma tumor murine model that enables rapid evaluation of treatments for 
multiple myeloma. International journal of oncology 28(6):1409-1417. 
205. Hofgaard PO, et al. (2012) A novel mouse model for multiple myeloma (MOPC315.BM) 
that allows noninvasive spatiotemporal detection of osteolytic disease. PloS one 
7(12):e51892. 
206. Radl J, De Glopper ED, Schuit HR, & Zurcher C (1979) Idiopathic paraproteinemia. II. 
Transplantation of the paraprotein-producing clone from old to young C57BL/KaLwRij 
mice. Journal of immunology 122(2):609-613. 
207. Roodman GD (2010) Myeloma bone disease (Humana, New York) pp x, 252 p. 
 72 
208. Vanderkerken K, et al. (1997) Organ involvement and phenotypic adhesion profile of 5T2 
and 5T33 myeloma cells in the C57BL/KaLwRij mouse. British journal of cancer 76(4):451-
460. 
209. Ahsmann EJ, et al. (1995) The SCID mouse as a model for multiple myeloma. British journal 
of haematology 89(2):319-327. 
210. LeBlanc R, et al. (2002) Proteasome inhibitor PS-341 inhibits human myeloma cell growth 
in vivo and prolongs survival in a murine model. Cancer research 62(17):4996-5000. 
211. Yaccoby S, Barlogie B, & Epstein J (1998) Primary myeloma cells growing in SCID-hu mice: a 
model for studying the biology and treatment of myeloma and its manifestations. Blood 
92(8):2908-2913. 
212. Fryer RA, et al. (2013) Characterization of a novel mouse model of multiple myeloma and 
its use in preclinical therapeutic assessment. PloS one 8(2):e57641. 
213. Urashima M, et al. (1997) The development of a model for the homing of multiple 
myeloma cells to human bone marrow. Blood 90(2):754-765. 
214. Mitsiades CS, Anderson KC, & Carrasco DR (2007) Mouse models of human myeloma. 
Hematology/oncology clinics of North America 21(6):1051-1069, viii. 
215. Chesi M, et al. (2008) AID-dependent activation of a MYC transgene induces multiple 
myeloma in a conditional mouse model of post-germinal center malignancies. Cancer cell 
13(2):167-180. 
216. Carrasco DR, et al. (2007) The differentiation and stress response factor XBP-1 drives 
multiple myeloma pathogenesis. Cancer cell 11(4):349-360. 
217. Laboratory TJ ( 
218. Ferlay J SI, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray, F 
(17072014) GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC 
CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 
2013. Available from: http://globocan.iarc.fr. 
219. Hsing AW & Chokkalingam AP (2006) Prostate cancer epidemiology. Frontiers in bioscience 
: a journal and virtual library 11:1388-1413. 
220. Eeles R, et al. (2014) The genetic epidemiology of prostate cancer and its clinical 
implications. Nature reviews. Urology 11(1):18-31. 
221. Mandair D, Rossi RE, Pericleous M, Whyand T, & Caplin ME (2014) Prostate cancer and the 
influence of dietary factors and supplements: a systematic review. Nutrition & metabolism 
11:30. 
222. Huncharek M, Haddock KS, Reid R, & Kupelnick B (2010) Smoking as a risk factor for 
prostate cancer: a meta-analysis of 24 prospective cohort studies. American journal of 
public health 100(4):693-701. 
223. Fowke JH, Howard L, Andriole GL, & Freedland SJ (2014) Alcohol Intake Increases High-
grade Prostate Cancer Risk Among Men Taking Dutasteride in the REDUCE Trial. European 
urology. 
224. Patel AR & Klein EA (2009) Risk factors for prostate cancer. Nature clinical practice. 
Urology 6(2):87-95. 
225. Gonzalgo ML & Isaacs WB (2003) Molecular pathways to prostate cancer. The Journal of 
urology 170(6 Pt 1):2444-2452. 
226. Iwata T, et al. (2010) MYC overexpression induces prostatic intraepithelial neoplasia and 
loss of Nkx3.1 in mouse luminal epithelial cells. PloS one 5(2):e9427. 
227. Koochekpour S (2011) Genetic and epigenetic changes in human prostate cancer. Iranian 
Red Crescent medical journal 13(2):80-98. 
228. Tindall D (Prostate cancer : biochemistry, molecular biology and genetics  pp xii, 522 pages. 
229. Kung HJ (2011) Targeting tyrosine kinases and autophagy in prostate cancer. Hormones & 
cancer 2(1):38-46. 
230. Alexanian A, Miller B, Chesnik M, Mirza S, & Sorokin A (2014) Post-translational regulation 
of COX2 activity by FYN in prostate cancer cells. Oncotarget 5(12):4232-4243. 
  73 
231. Dai B, et al. (2010) Compensatory upregulation of tyrosine kinase Etk/BMX in response to 
androgen deprivation promotes castration-resistant growth of prostate cancer cells. 
Cancer research 70(13):5587-5596. 
232. Dai B, et al. (2006) Tyrosine kinase Etk/BMX is up-regulated in human prostate cancer and 
its overexpression induces prostate intraepithelial neoplasia in mouse. Cancer research 
66(16):8058-8064. 
233. Qiu Y, Robinson D, Pretlow TG, & Kung HJ (1998) Etk/Bmx, a tyrosine kinase with a 
pleckstrin-homology domain, is an effector of phosphatidylinositol 3'-kinase and is 
involved in interleukin 6-induced neuroendocrine differentiation of prostate cancer cells. 
Proceedings of the National Academy of Sciences of the United States of America 
95(7):3644-3649. 
234. Figel S & Gelman IH (2011) Focal adhesion kinase controls prostate cancer progression via 
intrinsic kinase and scaffolding functions. Anti-cancer agents in medicinal chemistry 
11(7):607-616. 
235. Tam L, et al. (2007) Expression levels of the JAK/STAT pathway in the transition from 
hormone-sensitive to hormone-refractory prostate cancer. British journal of cancer 
97(3):378-383. 
236. Carrion-Salip D, et al. (2012) Androgen-independent prostate cancer cells circumvent EGFR 
inhibition by overexpression of alternative HER receptors and ligands. International journal 
of oncology 41(3):1128-1138. 
237. Di Lorenzo G, et al. (2002) Expression of epidermal growth factor receptor correlates with 
disease relapse and progression to androgen-independence in human prostate cancer. 
Clinical cancer research : an official journal of the American Association for Cancer 
Research 8(11):3438-3444. 
238. Soler M, et al. (2009) HER3 is required for the maintenance of neuregulin-dependent and -
independent attributes of malignant progression in prostate cancer cells. International 
journal of cancer. Journal international du cancer 125(11):2565-2575. 
239. Kwabi-Addo B, Ozen M, & Ittmann M (2004) The role of fibroblast growth factors and their 
receptors in prostate cancer. Endocrine-related cancer 11(4):709-724. 
240. Feng S, Dakhova O, Creighton CJ, & Ittmann M (2013) Endocrine fibroblast growth factor 
FGF19 promotes prostate cancer progression. Cancer research 73(8):2551-2562. 
241. Wozney JL & Antonarakis ES (2014) Growth factor and signaling pathways and their 
relevance to prostate cancer therapeutics. Cancer metastasis reviews. 
242. Wu J & Yu E (2014) Insulin-like growth factor receptor-1 (IGF-IR) as a target for prostate 
cancer therapy. Cancer metastasis reviews. 
243. Hellawell GO, et al. (2002) Expression of the type 1 insulin-like growth factor receptor is 
up-regulated in primary prostate cancer and commonly persists in metastatic disease. 
Cancer research 62(10):2942-2950. 
244. Rojas A, et al. (2011) IL-6 promotes prostate tumorigenesis and progression through 
autocrine cross-activation of IGF-IR. Oncogene 30(20):2345-2355. 
245. Hofer MD, et al. (2004) Expression of the platelet-derived growth factor receptor in 
prostate cancer and treatment implications with tyrosine kinase inhibitors. Neoplasia 
6(5):503-512. 
246. Iqbal S, et al. (2012) PDGF upregulates Mcl-1 through activation of beta-catenin and HIF-
1alpha-dependent signaling in human prostate cancer cells. PloS one 7(1):e30764. 
247. Vignarajan S, et al. (2014) Loss of PTEN stabilizes the lipid modifying enzyme cytosolic 
phospholipase A(2)alpha via AKT in prostate cancer cells. Oncotarget. 
248. McCubrey JA, et al. (2007) Roles of the Raf/MEK/ERK pathway in cell growth, malignant 
transformation and drug resistance. Biochimica et biophysica acta 1773(8):1263-1284. 
249. Karlou M, Tzelepi V, & Efstathiou E (2010) Therapeutic targeting of the prostate cancer 
microenvironment. Nature reviews. Urology 7(9):494-509. 
250. De Marzo AM, et al. (2007) Inflammation in prostate carcinogenesis. Nature reviews. 
Cancer 7(4):256-269. 
 74 
251. Bergers G & Benjamin LE (2003) Tumorigenesis and the angiogenic switch. Nature reviews. 
Cancer 3(6):401-410. 
252. Luo J, et al. (2014) Infiltrating bone marrow mesenchymal stem cells increase prostate 
cancer stem cell population and metastatic ability via secreting cytokines to suppress 
androgen receptor signaling. Oncogene 33(21):2768-2778. 
253. Ostman A & Augsten M (2009) Cancer-associated fibroblasts and tumor growth--
bystanders turning into key players. Current opinion in genetics & development 19(1):67-
73. 
254. Liu XH, et al. (2007) Androgen-induced Wnt signaling in preosteoblasts promotes the 
growth of MDA-PCa-2b human prostate cancer cells. Cancer research 67(12):5747-5753. 
255. Hofbauer LC & Khosla S (1999) Androgen effects on bone metabolism: recent progress and 
controversies. European journal of endocrinology / European Federation of Endocrine 
Societies 140(4):271-286. 
256. Elo TD, et al. (2010) Stromal activation associated with development of prostate cancer in 
prostate-targeted fibroblast growth factor 8b transgenic mice. Neoplasia 12(11):915-927. 
257. Varkaris A, Katsiampoura AD, Araujo JC, Gallick GE, & Corn PG (2014) Src signaling 
pathways in prostate cancer. Cancer metastasis reviews. 
258. McAninch JW, Lue TF, & Smith DR (2013) Smith and Tanagho's general urology / editors, 
Jack W. McAninch, Thomas F. Lue (McGraw-Hill Professional, New York) 18th Ed pp x, 758 
p. 
259. Noguez JH & Fantz CR (2014) Pathology Consultation on Prostate-Specific Antigen Testing. 
American journal of clinical pathology 142(1):7-15. 
260. Wright JL & Lange PH (2007) Newer potential biomarkers in prostate cancer. Reviews in 
urology 9(4):207-213. 
261. Klotz L & Emberton M (2014) Management of low risk prostate cancer: active surveillance 
and focal therapy. Current opinion in urology 24(3):270-279. 
262. Klotz L & Emberton M (2014) Management of low risk prostate cancer-active surveillance 
and focal therapy. Nature reviews. Clinical oncology 11(6):324-334. 
263. Chang AJ, Autio KA, Roach M, 3rd, & Scher HI (2014) High-risk prostate cancer-
classification and therapy. Nature reviews. Clinical oncology 11(6):308-323. 
264. Fan F, et al. (2014) Targeting Mcl-1 for multiple myeloma (MM) therapy: drug-induced 
generation of Mcl-1 fragment Mcl-1(128-350) triggers MM cell death via c-Jun 
upregulation. Cancer letters 343(2):286-294. 
 
 
